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PREDICTING PROBABILITY
INTRODUCTION
At the intersection of two rapidly developing areas of biotechnology, a
revolution is about to take place. Although this revolution involves reproduction,
it will not be sexual. A medical procedure, known as preimplantation genetic
diagnosis (PGD), combines genetic testing and assisted reproductive technology
(ART) to enable parents to screen their potential children before implantation for
genetic or chromosomal characteristics. The technology has been a godsend to
couples with family histories of genetic disorders and chromosomal mutations
causing infertility. However, expanding its use to permit prospective parents to
select embryos based on a wide array of genetic characteristics presents
substantial risks to individuals involved in the procedure and to society as a
whole.
Although PGD use has remained extremely limited due to technological
constraints, expense, and moderate success rates, recent advances in genetic
testing procedures will remove many of these obstacles and significantly increase
the benefits of its use. Better tests, providing better information, will expand the
use of this technology from embryos known to be at risk for serious disease -
preimplantation genetic diagnosis - to the testing of all or almost all in vitro
embryos for multiple genetic characteristics - preimplantation genetic screening
(PGS).1
Future couples might select their potential children based on knowledge of
their genetic susceptibility to serious diseases, like breast cancer2 and
Alzheimer's disease;3 their propensity for cardiac arrhythmia;4 the probability
that they will develop more common diseases, like diabetes;5 the probability that
they will have childhood asthma;6 their sex; 7 their likely body-mass index and
1. Throughout the paper, preimplantation genetic diagnosis (PGD) will refer to genetic and
chromosomal screening for diseases, and preimplantation genetic screening (PGS) will refer to
genetic and chromosomal screening for all other conditions. In addition, PGS will be used to
encompass both ideas at once.
2. See Rosalind A. Eeles, Future Possibilities in the Prevention of Breast Cancer:
Intervention Strategies in BRCAI and BRCA2 Mutation Carriers, 2 BREAST CANCER RES. 283
(2000).
3. See Charles R. Harrington et al., Influence of Apolipoprotein E Genotype on Senile
Dementia of the Alzheimer and Lewy Body Types: Significance for Etiological Theories of
Alzheimer's Disease, 145 AM. J. PATHOLOGY 1472 (1994).
4. See Daniel J. Gudbjartsson et al., Variants Conferring Risk of Atrial Fibrillation on
Chromosome 4q25, 448 NATURE 353 (2007).
5. See Jose C. Florez et al., TCF7L2 Polymorphisms and Progression to Diabetes in the
Diabetes Prevention Program, 355 NEw ENG. J. MED. 241 (2006).
6. See Miriam F. Moffat et al., Genetic Variants Regulating ORMDL3 Expression Contribute
to the Risk of Childhood Asthma, 448 NATURE 470 (2007).
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weight;8 their hair, eye, and skin color;9 their propensity for aggression;"° and
their likely height." As our knowledge of genetics expands, geneticists will be
able to test embryos for the presence of gene variants, known as alleles,
12
associated with a range of conditions through the use of a DNA microarray, a
testing device that can screen for thousands of alleles at one time. Combining
these genetic advances with ART procedures will permit parents to select
embryos based upon their potential future traits.'
3
While scientists and consumers pursue the promise of PGS, we must also
acknowledge the potential harms associated with its widespread adoption. Recent
studies suggest that while PGS has great potential, its benefits may not always
outweigh its risks. A number of variables contribute to the risks associated with
PGS. Assisted reproduction procedures performed as part of PGS, such as in
vitro fertilization (IVF), 14 intracytoplasmic sperm injection (ICSI),15 and embryo
7. See Medline Plus, Genetics, http://www.nlm.nih.gov/medlineplus/ency/article/002048.htm
(last visited Apr. 18, 2008).
8. See Angelo Scuteri et al., Genome-Wide Association Scan Shows Genetic Variants in the
FTO Gene Are Associated with Obesity-Related Traits, 3 PLoS GENETICS 1200 (2007),
http://www.plosgenetics.org/article/info%3Adoi%2F 10.1371%2Fjoumal.pgen.0030115 (follow
link to PDF version).
9. See Maarten T. Bastiaens et al., Melanocortin-1 Receptor Gene Variants Determine the
Risk of Nonmelanoma Skin Cancer Independently of Fair Skin and Red Hair, 68 AM. J. HUM.
GENETICS 884 (2001) (finding that the MC1R gene is associated with red hair and fair skin in
individuals of European descent); David L. Duffy et al., A Three-Single-Nucleotide Polymorphism
Haplotype in Intron 1 of OCA2 Explains Most Human Eye-Color Variation, 80 AM. J. HUM.
GENETICS 241 (2007).
10. See Kevin M. Beaver et al., A Gene x Gene Interaction between DRD2 and DRD4 Is
Associated with Conduct Disorder and Antisocial Behavior in Males, 3 BEHAV. & BRAIN
FUNCTIONS 30 (2007); Giovanni Frazzetto et al., Early Trauma and Increased Risk for Physical
Aggression During Adulthood: The Moderating Role of MAOA Genotype, 2 PLOS ONE 1 (2007),
http://www.plosone.org/article/info%3Adoi%2F10.1371 %2Fjoumal.pone.0000486 (follow link to
PDF version); Essi Viding & Uta Frith, Genes for Susceptibility to Violence Lurk in the Brain, 103
PROC. NAT'L ACAD. ScI. 6085 (2006).
11. See Jianfeng Xu et al., Major Recessive Gene(s) with Considerable Residual Polygenic
Effect Regulating Adult Height: Confirmation of Genomewide Scan Results for Chromosomes 6, 9,
and 12, 71 AM. J. HUM. GENETICS 646 (2002).
12. Alleles are different variations of a gene. If only one gene controlled eye color, alleles
would exist for blue, green, brown, and hazel eyes.
13. A number of companies are working on incorporating the DNA microarray and other high
throughput testing devices into ART procedures, and these developments are rapidly approaching
commercialization. See, e.g., Gene Security Network, http://www.genesecurity.net/services.html
(last visited Mar. 30, 2008) (stating that its high throughput technology will offer parents
information on all twenty-three chromosome pairs and multiple disease-linked genetic loci in
2008).
14. In vitro fertilization is a process through which eggs are removed from a woman's ovaries
VIII:2 (2008)
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biopsy, 16 are associated with increased risks to the embryo, the mother, and the
future child. Uncertainties inherent in the genetic testing process, such as
inaccurate genetic tests, 17 embryo mosaicism, 18 and low gene penetrance,1 9 have
and fertilized with sperm in a Petri dish. Embryos are cultured in the dish for two to five days and
then transferred to the uterus for implantation. See IVF-Infertility.com, Fertilization (Fertilisation),
http://www.ivf-infertility.com/ivf/standard/procedure/fertilization.php (last visited Apr. 18, 2008);
see also Jane Halliday, Outcomes of IVF Conceptions: Are They Different?, 21 BEST PRAC. & RES.
CLINICAL OBSTETRICS & GYNAECOLOGY 67 (2007) (finding that perinatal outcomes such as preterm
delivery, low birth weight and some birth defects occurred with increased frequency in single-child
(singleton) IVF births); Dorte Hvidtjorn et al., Cerebral Palsy Among Children Born After In Vitro
Fertilization: The Role of Preterm Delivery - A Population-Based, Cohort Study, 118 PEDIATRICS
475 (2006) (finding that IVF procedures that result in preterm deliveries posed an increased risk of
cerebral palsy); Reija Klemetti et al., Health of Children Born as a Result of In Vitro Fertilization,
118 PEDIATRICS 1819 (2006) (finding that singleton IVF babies had higher incidences of perinatal
problems, congenital malformations and problems of the genitourinary system than naturally
conceived children; interestingly, the study also revealed a slight decrease in respiratory disease in
children born via IVF).
15. ICSI, a procedure in which a single sperm is injected into the egg through the use of a
micropipette, is commonly used in IVF and PGS procedures to ease fertilization when there are
abnormalities in the function, number or quality of the sperm. See Am. Soc'y for Reprod. Med.,
Patient's Fact Sheet: Intracytoplasm Sperm Injection (ICSI) (2001), available at http://www.
asrm.org/PatientsiFactSheets/ICSI-Fact.pdf; see also M. Bonduelle et al., A Multi-Centre Cohort
Study of the Physical Health of 5-Year-Old Children Conceived After Intracytoplasmic Sperm
Injection, In Vitro Fertilization and Natural Conception, 20 HUM. REPROD. 413, 416 (2005)
(finding that 4.2% of children born via ICSI have a major congenital malformation, which is 2.77
times the rate of children naturally conceived; this result remained statistically significant when
controlled for age, country, maternal age, education level, social class, maternal smoking habits,
drinking, and number of previous pregnancies).
16. Embryo biopsy is the procedure in which the clinician removes one to two cells from an
eight-cell embryo for genetic testing. See Sebastiaan Mastenbroek et al., In Vitro Fertilization with
Preimplantation Genetic Screening, 357 NEw ENGL. J. MED. 9 (2007) (suggesting that the decrease
from the live birthrate associated with IVF procedures alone (37%) to the live birthrate associated
with PGS procedures (25%) might result from the embryo biopsy).
17. SUSANNAH BARUCH ET AL., GENETICS & PUB. POLICY CTR., PREIMPLANTATION GENETIC
DIAGNOSIS: A DISCUSSION OF CHALLENGES, CONCERNS, AND PRELIMINARY POLICY OPTIONS
RELATED TO THE GENETIC TESTING OF HUMAN EMBRYOS 5-6 (2004), available at
http://www.dnapolicy.org/images/reportpdfs/PGDDiscussionChallengesConcerns.pdf.
18. Mosaic embryos contain certain cells with chromosomal and genetic structures that differ
from those in the rest of the embryo. See Medline Plus, Mosaicism, http://www.nlm.nih.gov/
medlineplus/ency/article/001317.htm (last visited Mar. 15, 2008). If tests are performed on these
cells, they will provide an inaccurate depiction of the overall embryo.
19. Gene penetrance refers to the likelihood that the presence of a gene will result in the
specific physical characteristic or phenotype associated with the gene. Some genes have one
hundred percent penetrance, such that presence of the gene indicates that the resulting individual
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also lead to embryo misdiagnosis, rendering the procedure ineffective. More
broadly, widespread use of the technique can harm not only the individuals
involved in it, but also society in general by increasing discrimination,
stigmatization, and health disparities. The potential for individual and social
harm resulting from these risks grows in proportion to the use and number of
genetic tests available for PGS.
Now is the time for the United States to consider the potential impacts of
PGS, and decide what role, if any, the federal government should play in
overseeing its use. Over the past few years, a number of scholars have called for
regulation of ART procedures in the United States. 20 This Article offers further
evidence in support of more general ART regulation by examining the risks and
benefits associated with recent advances in reproductive genetic testing and PGS.
In developing an appropriate response to recent advances in assisted
reproductive technology and genetic testing, the United States should address
three critical questions: 1) Does PGS need oversight?; if so, 2) What entities can
best regulate PGS?; and 3) How should PGS be regulated?
After briefly describing the technologies involved, this Article will consider
will definitely have the disorder or characteristic. Other genes have lower penetrance, indicating
that only some individuals with the gene will have the disorder or condition. Human Genome
Project, Evaluating Gene Tests: Some Considerations, http://www.oml.gov/sci/techresources/
HumanGenome/resource/testeval.shtml (last visited Mar. 15, 2008).
20. See, e.g., FRANCIS FUKUYAMA & FRANCO FURGER, BEYOND BIOETHICS; A PROPOSAL FOR
MODERNIZING THE REGULATION OF HUMAN BIOTECHNOLOGIES 293-300 (2006); June Carbone &
Paige Gottheim, Markets, Subsidies, Regulation, and Trust: Building Ethical Understandings into
the Market for Fertility Services, 9 J. GENDER, RACE & JUST. 509 (2006); Alexander N. Hecht, The
Wild Wild West: Inadequate Regulation of Assisted Reproductive Technology, 1 Hous. J. HEALTH
L. & POL'Y 227 (2001); Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our
Eugenics Past-Present, and Future?, 36 CONN. L. REV. 125 (2003) [hereinafter Malinowski,
Choosing]; Michael J. Malinowski, A Law-Policy Proposal To Know Where Babies Come from
During the Reproduction Revolution, 9 J. GENDER, RACE & JUST. 549 (2006) [hereinafter
Malinowski, A Law-Policy Proposal]; Lars Noah, Assisted Reproductive Technologies and the
Pitfalls of Unregulated Biomedical Innovation, 55 FLA. L. REv. 603 (2003); Vicki G. Norton,
Unnatural Selection: Nontherapeutic Preimplantation Genetic Screening and Proposed
Regulation, 41 UCLA L. REv. 1581 (1994); Eric Parens & Lori P. Knowles, Reprogenetics and
Public Policy: Reflections and Recommendations, 33 HASTINGS CENTER REP. S18-21 (2003);
Jennifer L. Rosato, The Children of ART (Assisted Reproductive Technology): Can the Law Protect
Them from Harm?, 2004 UTAH L. REv. 57 (2004); Lindsey A. Vacco, Preimplantation Genetic
Diagnosis: From Preventing Genetic Disease to Customizing Children. Can the Technology Be
Regulated Based on the Parents' Intent?, 49 ST. LOUIS L.J. 1181 (2005); Aaron R. Fahrenkrog,
Note, A Comparison of International Regulation of Preimplantation Genetic Diagnosis and a
Regulatory Suggestion for the United States, 15 TRANSNAT'L L. & CONTEMP. PROBS. 757, 779
(2006); Note, Guiding Regulatory Reform in Reproduction and Genetics, 120 HARV. L. REv. 574
(2006).
VIl:2 (2008)
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each of these three questions, starting with an examination of the medical and
social risks associated with PGS. Given these risks, the Article critiques the
current lack of oversight in the United States. It then examines the ability of
existing regulatory options to address the coming dilemma of reproductive
genetic selection. Finding the current options wanting, the Article concludes with
an outline for the development of a regulatory infrastructure for ART.
The proposed regulatory infrastructure is based upon the relevant
stakeholders and their interests. With respect to PGS, the stakeholders include
prospective parents, ART providers, children born via the procedure, and
members of society affected by its use. To balance and protect their interests, this
Article argues for the creation of an independent federal entity, the Assisted
Reproductive Technology Authority (ARTA). Initially, ARTA should pursue
regulation that will benefit all or most stakeholders, such as ensuring the safety
and efficacy of all procedures involved in ART; improving access to information
regarding the risks and benefits of various uses of ART; and analyzing the effect
of ART, especially PGS, on both individuals and society.
ARTA should then focus on developing a framework to address
stakeholders' conflicting interests. The most glaring conflict associated with PGS
will arise from parental and practitioner desires to conduct procedures or screen
embryos in ways that threaten harm to other individuals or society as a whole.
Initially, ARTA should monitor the use patterns of ART and PGS to determine
whether these interests conflict in ways that will result in substantial harm to
other members of society. As PGS use expands, it will be imperative to have a
working infrastructure to monitor potential harms and address these conflicts as
they arise.
While the full scope of ethical, social, and technological challenges
associated with ART and PGS is not yet visible, as is common at the outset of the
use of most disruptive technologies, the United States can take steps to address
current concerns associated with the technology and prepare for future dilemmas.
Establishing the principles on which to base policy decisions in the future, as
well as the infrastructure required to do so, will greatly improve the ability to
assimilate and respond quickly to new information on the scientific
developments, health risks, and public sentiment associated with PGS. Given the
potential of these recent technological advances to alter our reproductive
practices dramatically and permanently, we can no longer ignore the questions of
whether and how we should regulate ART and, more specifically, PGS.
Rather than leaving regulation to professional societies, states, or Congress,
the United States can best monitor and regulate ART via an independent federal
agency. Unlike prior calls for change, this Article proposes a novel balancing
approach to guide the way the federal agency addresses expanding PGS
technology, along with a mechanism for monitoring the effects of PGS on
individuals and society. Part I provides background information on the current
HeinOnline -- 8 Yale J. Health Pol'y L. & Ethics 289 2008
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and future capabilities of PGS. Part II argues that PGS should be subject to
oversight and regulation, and Part III considers which entities are best suited to
oversee PGS. Finally, Part IV proposes a structure and an agenda for a new
regulatory agency to govern ART practice in the United States.
I. PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING
PGD currently offers prospective parents the opportunity to select embryos
based on their susceptibility to a range of genetic and chromosomal disorders,
such as Down syndrome, 21 Tay-Sachs, 22 and cystic fibrosis. 23 To perform PGD,
parents must go through a cycle of IVF, in which a clinician harvests a number of
eggs from the woman and combines each with sperm in a Petri dish in hopes of
producing healthy embryos. Some eggs will not fertilize successfully; others will
be fertilized, but will not successfully divide. For those embryos that successfully
divide, on the third day of growth, when they consist of about eight cells, the
clinician will perform an embryo biopsy to remove a cell or two for genetic or
chromosomal testing.24 The testing must be completed within about forty-eight
hours for the embryo to remain useful.25
21. Down syndrome impacts one in 733 live births. Nat'l Down Syndrome Soc'y, Information
Topics, http://www.ndss.org/index.php?option=com-content&task=view&id= 812&Itemid=95
(last visited Mar. 30, 2008). The disease is associated with impairment of physical growth, reduced
cognitive ability, congenital heart defects and distinctive facial features. Nat'l Inst. of Child Health
& Human Dev., Down Syndrome, http://www.nichd.nih.gov/health/topics/Down-Syndrome.cfm
(last visited Apr. 5, 2008).
22. Tay-Sachs disease causes a relentless deterioration of mental and physical abilities. Over
time, the disease inhibits the child's ability to see, hear, and swallow. The muscles progressively
deteriorate, and paralysis eventually results. Most children die by the age of four. See, e.g., Medline
Plus, Tay-Sachs Disease, http://www.nlm.nih.gov/medlineplus/taysachsdisease.html (last visited
Mar. 15, 2008).
23. Cystic fibrosis is a genetic disease that affects the mucus and sweat glands. Sticky mucus
caused by the disorder leads to impairment throughout the entire body, affecting the lungs,
pancreas, liver, intestines, sinuses, and sex organs. These difficulties persist over the life of the
individual; with treatment, individuals with cystic fibrosis generally live longer than thirty-five
years. See Medline Plus, Cystic Fibrosis, http://www.nlm.nih.gov/medlineplus/cysticfibrosis.html
(last visited Mar. 15, 2008).
24. See, e.g., IVF-Infertility.com, Preimplantation Genetic Diagnosis (PGD), http://www.ivf-
infertility.com/ivf/pgd.php (last visited Apr. 5, 2008).
25. The embryo should then be transferred to the uterus on or before the fifth day after
fertilization, As a result, genetic testing laboratories have less than a forty-eight-hour window to
receive DNA samples from the embryo, conduct the genetic tests, and provide the results to the
PGS clinic and transfer the embryo to the uterus of the woman for implantation. Interview with
Barry Behr, Director, IVF/ART Laboratories, Dep't of Obstetrics & Gynecology, Stanford Sch. of
Med., in Palo Alto, Cal. (Oct. 16, 2006).
VIII:2 (2008)
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After getting the test results, the clinician usually transfers two to three
embryos that meet the parents' approval to the uterus in hopes of establishing
pregnancy.2 6 Embryos with undesired genes are typically discarded or donated to
research.27 Over 12,000 cycles of PGD have been performed worldwide since its
creation in 1989, with the number of cycles growing substantially every year.28
A. Current PGS Use
Scientists can now examine DNA through a number of different methods,
each with its own benefits and drawbacks for PGS use. Different tests are used
depending on whether the goal is to examine the chromosomes or the genes.
Chromosomal structure analysis, performed by fluorescence in situ hybridization
(FISH), examines whether the embryo has two copies of a chromosome and
29
whether those copies are intact. While FISH analysis provides useful
information on common chromosomal abnormalities, it cannot provide
information on all forty-six chromosomes because only five to nine
chromosomes can be examined accurately at one time.30 To examine a specific
gene on a chromosome, geneticists have to make numerous copies of the DNA
26. Requirements for an embryo to meet parents' approval vary, including having the correct
number of chromosomes, being the desired sex or tissue type, or being unaffected with a genetic
disease.
27. Interview with Barry Behr, supra note 25.
28. See SUSANNAH BARUCH, DAVID KAUFMAN & KATHY L. HUDSON, GENETICS & PUB. POLICY
CTR., GENETIC TESTING OF EMBRYOS: PRACTICES AND PERSPECTIVES OF U.S. IVF CLINICS 3 (2006),
available at http://www.dnapolicy.org/resources/PGDSurveyReportFertilityandSterilitySeptember
2006withcoverpages.pdf (reporting a survey of "substantially all" U.S. ART clinics; 45% of these
clinics responded, and together these clinics reported conducting 3379 cycles of PGS in 2005);
Yury Verlinsky et al., Over a Decade of Experience with Preimplantation Genetic Diagnosis: A
Multicenter Report, 82 FERTILITY & STERILITY 292, 293 (2004) (reporting in August 2004 that 4748
cycles of PGD had been performed in three of the world's most active PGD centers). According to
a recent report from ESHRE, forty-five clinics worldwide conducted 12,397 cycles of PGD and
PGS between 1997 and 2004, with 3358 performed in 2004 alone. J.C. Harper et al., ESHRE PGD
Consortium Data Collection VII: Cycles from January to December 2004 with Pregnancy Follow-
Up to October 2005, 23 HUM. REPROD. 741, 742 (2008). If this rate has remained fairly constant, I
conservatively estimate that at least 25,000 cycles of PGD have been performed worldwide to date.
29. See Dagan Wells & Brynn Levy, Cytogenetics in Reproductive Medicine: The Contribution
of Comparative Genomic Hybridization (CGH), 25 BIOESSAYS 289, 291-92 (2003). FISH detects
chromosomal abnormalities by labeling DNA probes that are perfect complements to the
chromosomal region of interest with a fluorescent molecule. When mixed with sample DNA from
the embryo, the probes will attach to their complementary chromosomal region on the embryo
DNA, and the fluorescent molecules will emit colored signals to indicate certain abnormalities.
30. Id.
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region of interest through a process known as polymerase chain reaction (PCR).3"
Conducting PCR for a single gene takes a significant amount of time, which
limits the number of tests that can be performed during the forty-eight hours
available for testing.
32
1. Chromosomal Analysis
Chromosomal abnormalities can cause embryo death or lead to significant
disorders in children.33 While normal embryos have twenty-two pairs of
autosomal chromosomes and one pair of sex chromosomes, abnormal embryos
often have too many or too few copies of a chromosome, a condition known as
aneuploidy. The most serious aneuploidies are lethal. PGS has been used to
improve fertility by allowing parents to avoid the transfer of aneuploid
embryos. 34 In current IVF practice, clinicians examine the shape and structure of
embryos to determine which embryos are healthiest.35 This physical examination,
otherwise known as morphology analysis, fails to identify chromosomal
abnormalities that occur in approximately 30% to 60% of embryos in women
over thirty-five.36 In theory, PGS should improve IVF success rates by allowing
clinicians to identify chromosomal abnormalities that are undetectable by looking
at the physical features of the embryo, although whether this improvement occurs
in practice has been the subject of recent debate within the ART community.37
31. See, e.g., Harper et al., supra note 28, at 746-47 (listing numerous conditions for which
PCR is used); C.S. Salvado, A.O. Trounson & D.S. Cram, Towards Preimplantation Diagnosis of
Cystic Fibrosis Using Microarrays, 8 REPROD. BIOMEDICINE ONLINE 107, 107-08 (2003).
32. Interview with Barry Behr, supra note 25.
33. March of Dimes, Chromosomal Abnormalities, http://www.marchofdimes.com/
professionals/14332 1209.asp (last visited Apr. 5, 2008).
34. See V. Baltaci et al., Relationship Between Embryo Quality and Aneuploidies, 12 REPROD.
BIOMEDICINE ONLINE 77 (2005); Y. Verlinsky et al., Preimplantation Testing for Chromosomal
Disorders Improves Reproductive Outcome of Poor-Prognosis Patients, 11 REPROD. BIOMEDICINE
ONLINE 219 (2005). But see Mastenbroek et al., supra note 16, at 13 (demonstrating that PGS use
to screen for chromosomal abnormalities in infertile women of advanced maternal age decreased
the likelihood that the woman will become pregnant when compared to traditional IVF).
35. Embryos with a more spherical shape that have progressed to a mature blastocyst state with
evenly sized cells may be more promising candidates for transfer to the uterus. See, e.g., Baltaci et
al., supra note 34, at 77; Santiago Munn&, Chromosome Abnormalities and Their Relationship to
Morphology and Development of Human Embryos, 12 REPROD. BIOMEDICINE ONLINE 234, 245
(2006).
36. Munn6, supra note 35, at 245 (2005) (finding a chromosomal abnormality frequency of
30% for women aged thirty-five to thirty-nine and 60% for women over forty).
371 See id. at 248. But see Mastenbroek et al., supra note 16, at 15-17. The medical evidence
does not yet fully support the idea that PGS can improve IVF success rates. Clinicians disagree
about whether the improvement in embryo selection provided by PGS outweighs any additional
VIII:2 (2008)
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The use of PGS to screen for chromosomal structure can also detect which
embryos will develop significant disorders. Infants can survive with three copies
risk to the embryo development caused by conducting the embryo biopsy required for PGS.
Mastenbroek et al. found that in women of advanced maternal age, PGS was associated with
reduced ongoing pregnancy rates from 37% to 25%, and reduced live birth rates from 35% to 24%
when compared with traditional IVF. Id. at 13. This study is the second large, multi-center,
randomized controlled trial to investigate the benefits of PGS in women of advanced maternal age,
a large subset of the infertility population. Id. at 10, 15. Despite these results, the underlying theory
that selecting embryos based upon the presence of an intact set of chromosomes should improve
pregnancy and live birth rates has not been disputed. Mastenbroek et al. offered numerous possible
explanations for the difference in pregnancy rates. Id. at 15-17. First, the embryo biopsy hindered
implantation and development. Id. at 16. This could result from either the removal process in
general or the technique used by researchers. Other PGS practitioners have questioned the quality
of the embryo biopsy procedures performed, as approximately 20% of embryos in the PGS group
had "undetermined" chromosomal status compared with 5% in experienced laboratories. See id. at
16 tbl. 4; Preimplantation Genetic Diagnosis Pioneers from the USA and Europe Refute New
England Journal of Medicine Article, Med. News Today, July 10, 2007,
http://www.medicalnewstoday.com/articles/76269.php [hereinafter PGD Pioneers]. When
transferred, these embryos had only a 6% implantation rate, significantly lower than that of
chromosomally "normal" PGS embryos (16.8%) and IVF embryos that did not undergo PGS
(14.8%). Mastenbroek et al., supra note 16, at 15-16. Of the 642 embryos transferred to the uterus
after PGS in this study, 100 were of undetermined status; this lowered the implantation, pregnancy
and live birth rates associated with PGS in the study. Id. at 13; PGD Pioneers, supra. Secondly,
researchers tested only one-third of the chromosomes, enabling some chromosomally abnormal
embryos to be classified as "normal" and transferred. Mastenbroek et al., supra note 16, at 11, 16.
These challenges can be alleviated through the use of DNA microarrays, and other advances in
genetic testing technology can provide information on all twenty-three pairs of chromosomes. Id. at
16. Third, embryos created through IVF tend to be mosaic, a condition in which not all cells in the
embryo have the same chromosomal structure, which can cause errors in classification. Id.; see also
supra note 18 and accompanying text. For instance, a mosaic embryo with a majority of normal
cells could be labeled "abnormal." Improvements in genetic testing and embryo biopsy procedures
may enable researchers to identify mosaic embryos in the future. Finally, more embryos from the
PGS group were formed through ICSI than in the control group, also potentially compromising the
integrity of the PGS embryos. Mastenbroek et al., supra note 16, at 16 tbl. 4. More research should
be performed to determine the cause of the reduction in pregnancy and live birth rates. In the
meantime, PGS use for infertility should be performed only in cases of repeat miscarriage and
recurrent IVF failure. The use of PGS for infertility is most beneficial for couples that have
experienced repeated miscarriages or otherwise have a poor prognosis related to the chromosomes.
See Verlinsky et al., supra note 34, at 221 (demonstrating that in a group of poor-prognosis
patients, PGS increased the implantation rate five-fold, cut the rate of spontaneous abortion by
more than half, and more than doubled the take home baby rate in comparison to prior IVF cycles);
see also Santiago Munn& et al., Preimplantation Genetic Diagnosis Significantly Reduces
Pregnancy Loss in Infertile Couples: A Multicenter Study, 85 FERTILITY & STERILITY 326, 329
(2006).
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(trisomies) of chromosomes 8, 9, 13, 18, and 21 and substantial deletions
(monosomies or partial monosomies) of regions on chromosomes 4, 5, and 15.38
Each trisomy or monosomy is associated with a specific disorder, most of which
result in mental retardation and premature death. 39 The most common aneuploidy
disorder is Down syndrome (trisomy 21). 40 In addition to having too many or too
few copies of a chromosome, abnormalities can also result when chromosomes
break and, in some cases, reattach to other chromosomes - chromosomal
translocation - which can lead to certain kinds of cancer and other
abnormalities.4t
Chromosomal testing can also be used for sex selection. Because males have
only one copy of the X chromosome, mutations on that chromosome can result in
disorders in male offspring.42 Sex selection is often performed to select against
38. Trimsomies include Trisomy 8 (Warkany Syndrome), Trisomy 9, Trisomy 13 (Patau
Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 21 (Down Syndrome), and Trisomy 22
(Cat's Eye Syndrome); monosomies include Monosomy 4 (Wolf-Hirschhom Syndrome),
Monosomy 5 (Cri du chat), Monosomy 15 (Angelman Syndrome/Prader-Willi Syndrome). See
Genetics Home Reference, Cri-du-chat Syndrome, http://ghr.nlm.nih.gov/condition=
criduchatsyndrome (last visited Apr. 18, 2008); Genetics Home Reference, Prader-Willi Syndrome,
http://ghr.nlm.nih.gov/condition=praderwillisyndrome (last visited Apr. 18, 2008); Healthline,
Trisomy 8 Mosaicism Syndrome, http://www.healthline.com/galecontent/trisomy-8-mosaicism-
syndrome (last visited Apr. 18, 2008); Medline Plus, Down Syndrome, http://www.nlm.nih.gov/
medlineplus/downsyndrome.html (last visited Apr. 18, 2008); Medline Plus, Trisomy 13,
http://www.nlm.nih.gov/medlineplus/ency/article/001660.htm (last visited Apr. 18, 2008); Medline
Plus, Trisomy 18, http://www.nlm.nih.gov/medlineplus/ency/article/001661.htm (last visited Apr.
18, 2008); Online Mendelian Inheritance in Man, Wolf-Hirschhom Syndrome,
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=194190 (last visited Apr. 18, 2008);
WebMD, Chromosome 9, Trisomy Mosaic, http://children.webmd.com/chromosome-9-trisomy-
mosaic (last visited Apr. 18, 2008); WebMD, Chromosome 22, Trisomy Mosaic,
http://children.webmd.com/chromosome-22-trisomy-mosaic (last visited Apr. 18, 2008).
39. See sources cited supra note 38.
40. See National Down Syndrome Society, supra note 21; see also Online Mendelian
Inheritance in Man, Down Syndrome, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=
190685 (last visited Mar. 31, 2008).
41. The Philadelphia chromosome is an example of a reciprocal translocation where a portion
of both the ninth chromosome and the twenty-second chromosome break off and reattach on the
other chromosome. The Philadelphia chromosome causes the malignant transformation in chronic
myelogenous leukemia, a form of cancer that weakens a patient's immune system and ability to
fight infection. See Michael Savona & Moshe Talpaz, Getting to the Stem of Chronic Myeloid
Leukaemia, 8 NATURE REV. CANCER 341 (2008); Online Mendelian Inheritance in Man, Leukemia,
Chronic Myeloid, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=608232 (last visited Mar.
31, 2008).
42. Richard Twyman, X-Linked Diseases, HUM. GENOME, Apr. 16, 2003,
http://genome.wellcome.ac.uk/doc-wtd02085 I.html.
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all male embryos produced by a couple at risk for X-linked disorders in cases
where no specific genetic test for the disorder exists.43 As scientists develop more
specific gene tests for disorders on the X chromosome, the need for sex selection
for medical purposes will decrease. Sex selection for non-medical purposes, such
as family balancing, however, continues to increase. a
Chromosomal analysis for medical purposes represents the most common
use of preimplantation screening in the United States. The Genetics and Public
Policy Center in Washington, D.C. recently surveyed 137 ART clinics in the
United States and found that out of the 3379 PGD cycles they performed in 2005,
66% of the cycles were for aneuploidy (2197), 9% were for chromosomal
translocations (403), and 3% were for X-linked diseases (96). 45 The Genetics and
Public Policy Center also found that 42% of ART clinics reported that they had
enabled parents to choose the sex of their child for non-medical reasons, such as
family balancing or parental preference.46 In addition, after undergoing PGS to
screen their embryos for chromosomal disorders, 35% of clinics gave parents the
option to select girls and boys for implantation from among the remaining
healthy embryos.
47
2. Genetic Analysis
In contrast to analyzing entire chromosomes, clinicians can also use PGD to
look for specific genetic traits. The Genetics and Public Policy Center survey
found that clinicians performed 12% of PGD procedures to avoid transferring
embryos that would develop severe genetic disorders, 8 such as Fanconi
anemia,49 cystic fibrosis, and Tay-Sachs. Often these disorders begin early in life
and have no known cure. Couples have also begun to screen embryos for late-
onset conditions that do not present until adulthood, such as Huntington's disease
43. BARUCH, KAUFMAN & HUDSON, supra note 28, at 5.
44. See id. at 6 (indicating that "sex selection [was] frequently mentioned" as a source of
"ethical questions" for clinics).
45. See id. at 3.
46. Id.
47. Id. at 6.
48. See id. at 4 (stating that 12% of reported cycles were provided to detect autosomal single
gene disorders).
49. Fanconi anemia is a rare, recessive blood disorder that is associated with an increased
incidence of tumor growth and failure of the bone marrow to produce blood cells. Many patients
develop acute myelogenous leukemia and die at a young age (between twenty and thirty years).
Nat'l Heart & Lung Inst., Disease and Conditions Index, What Is Fanconi Anemia?,
http://www.nhlbi.nih.gov/health/dci/Diseases/fanconi/fanconi-whatis.html (last visited Mar. 30,
2008); see also Harper et al., supra note 28, at 743-44 (grouping Fanconi anemia in a list of
monogenic diseases).
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and Alzheimer's disease, and for genetic predispositions to diseases like
hereditary breast cancer and colon cancer.50
Genetic analysis can also permit parents to select embryos based on their
non-medical traits. Couples have undergone PGS to select an embryo that could
be a cord blood donor for a sick family member by virtue of having the same
genetic Human Leukocyte Antigen (HLA) or tissue type.51 In families with a
history of a genetic disorder, such as Fanconi anemia, parents can use PGS to
select unaffected embryos that can be tissue donors for their sick child. If the sick
child has a disease without a genetic cause, parents can also use PGS solely to
select embryos that could be a tissue type match for the sick child. This use of
PGS has inspired much ethical debate around whether it is appropriate to create a
child to save another, or to put the future child at risk to save another.52 Only 6%
of ART clinics surveyed have provided tissue typing in the absence of testing for
a genetic disorder.53
Some individuals have sought to use PGS to select embryos that will fit into
their culture by choosing embryos that have a specific genetic condition, such as
deafness or acondroplasia (dwarfism) 54 Three percent of ART clinics surveyed
have enabled couples to use PGS to select for disabilities.55 While embryo
selection for non-medical purposes still remains a small percentage of overall
PGS use, this type of selection will continue to grow as the number of genetic
tests increases and public knowledge of PGS expands.
B. Limitations on Current PGS Use
Currently PGS has a number of drawbacks that limit its use. The largest of
these results from its reliance on the IVF process to create embryos for genetic
and chromosomal testing. IVF is expensive and unpleasant. One cycle of IVF
ranges in price from $10,000 to $12,000.56 While a handful of states require
insurance companies to cover all or a portion of the costs associated with IVF, a
substantial percentage of IVF patients remain uncovered by insurance and are
50. See BARUCH, KAUFMAN & HUDSON, supra note 28, at 4.
51. Id. at 5.
52. See, e.g., S. Sheldon & S. Wilkinson, Should Selecting Saviour Siblings Be Banned?, 30 J.
MED. ETHICS 533 (2004). The United Kingdom originally banned the use of PGS solely to create a
child with a matching tissue type, but then overturned the decision in light of public outcry and
more liberal policies in other countries.
53. See BARUCH, KAUFMAN & HUDSON, supra note 28, at 5.
54. Id.; see also Darshak M. Sanghavi, Wanting Babies Like Themselves, Some Parents
Choose Genetic Defects, N.Y. TIMES, Dec. 5, 2006, at F5.
55. See BARUCH, KAUFMAN & HUDSON, supra note 28, at 5.
56. BARUCH ET AL., supra note 17, at 22.
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forced to pay for the procedure out of pocket.57
Given the discomfort and inconvenience associated with IVF,58 women may
be reluctant to try PGS. In order to stimulate the ovaries to produce eggs for the
IVF cycle, women must undertake daily hormone injections for ten to twelve
days.59 The mature eggs must be retrieved through a minor surgical procedure
conducted under sedation or anesthetic.60 Egg retrieval can result in pain,
bleeding, nausea, and vomiting.61 In addition, the long-term risks of fertility
drugs remain largely unexamined and unknown.
62
In addition to the problems associated with IVF, certain features of PGS also
limit its use. PGS testing adds an additional $2500-$7000 to the price of IVF,
making it even more financially inaccessible.63 Second, the embryo biopsy
procedure may hinder embryo implantation and development, reducing live birth
success rates.64 Finally, the amount of information currently available through
PGS testing is significantly constrained by genetic testing restrictions and the
fragile state of the preimplantation embryo.65 Having only the biopsied cell's
DNA available for testing greatly limits testing options and accuracy. Currently,
couples must choose between conducting an analysis on five to nine
chromosomes and conducting one to two genetic tests,66 as these tests examine
57. DEBORAH SPAR, THE BABY BUSINESS: How MONEY, SCIENCE, AND POLITICS DRIVE THE
COMMERCE OF CONCEPTION 213 (2006).
58. See, e.g., IVF-Infertility.com, Egg Collection, http://www.ivfinfertility.com/ivf/standard
/procedure/egg.php (last visited Apr. 4, 2008); IVF-Infertility.com, Superovulation, http://www.ivf-
infertility.com/ivf/standard/procedure/superovulation.php (last visited Apr. 4, 2008).
59. See IVF-Infertility.com, Superovulation, supra note 58. In up to 3% of women, these
hormones can result in moderate or severe ovarian hyperstimulation, a serious condition that results
in hospitalization and in rare cases death. See David A. Grainger, Linda M. Fraizer & Courtney A.
Rowland, Preconception Care and Treatment with Assisted Reproductive Technologies, 10
MATERNAL & CHILD HEALTH J. S161, S162 (2006). Some researchers and patients are concerned
that fertility drugs may lead to an increased risk of hormone-dependent cancers, such as breast,
ovarian, and uterine cancers. While the limited research that has been done does not support a
relationship between fertility drugs and breast and ovarian cancer, more research is imperative to
determine the long-term cancer risks of fertility drugs. See ASSESSING THE MEDICAL RISKS OF
HUMAN OOCYTE DONATION FOR STEM CELL RESEARCH: WORKSHOP REPORT 2 (Linda Giudice,
Eileen Santa & Robert Pool eds., 2007), available at http://www.nap.edu/catalog.php?
record id=l 1832 [hereinafter WORKSHOP REPORT].
60. See IVF-Infertility.com, Egg Collection, supra note 58.
61. Id.
62. WORKSHOP REPORT, supra note 59, at 2.
63. Reprod. Genetics Inst., Price List as of 1/05, www.reproductivegenetics.com/docs/pgd-
pricelistO022305.pdf (last visited Mar. 31, 2008).
64. See Mastenbroek et al., supra note 16.
65. See supra note 25.
66. BARUCH, KAUFMAN & HUDSON, supra note 28, at 2.
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the DNA in different ways. These technological constraints have greatly limited
the information PGS can provide prospective parents, and therefore the use of the
procedure in general.
Even if scientists resolve these technical dilemmas, current understanding of
gene function and how genes produce certain physical characteristics or
phenotypes is also limited. For most common heritable diseases, like heart
disease and diabetes, the genetic contribution to the development of the disorder
is complicated. "[T]he interplay of multiple genes and multiple non-genetic
factors, not a single allele, usually dictates disease susceptibility and response to
treatments." 67 Computer scientists, geneticists, and statisticians are developing
strategies to decipher the role of gene-gene interaction and gene-environment
interaction in common disorders and individual characteristics. 68 As our
understanding of these interactions expands along with our ability to test for
numerous genes at one time, the value of the information PGS can provide to
couples will grow quickly and exponentially.
Alleviating these technical and informational difficulties may tip the balance
for many couples in favor of using PGS. This hope of an increased market
demand has inspired numerous scientists to try to resolve the technical and
financial challenges associated with PGS.
C. Future Capabilities of PGS
Even with current limitations, recent innovations in genetic testing will soon
increase the information available to prospective parents through PGS by
enabling them to simultaneously evaluate embryos on both their chromosomal
integrity and the presence of numerous gene variants. 69 The most promising
advance involves the use of DNA microarrays. A DNA microarray provides a
medium for the orderly arrangement and matching of known and unknown DNA
samples.7° When performed for a full sample of DNA, microarrays can identify
67. Francis S. Collins et al., U.S. Nat'l Hum. Genome Res. Inst., A Vision for the Future of
Genomics Research: A Blueprint for the Genomic Era, 422 NATURE 835, 840 (2003).
68. Id. at 838; New Technology Predicted To Revolutionize Genetic Analysis of
Preimplantation Embryos, MED. NEWS TODAY, Oct. 22, 2006, http://www.medicalnewstoday.com
/articles/54745.php [hereinafter New Technology Predicted].
69. See Munn&, supra note 35; Dagan Wells, Advances in Preimplantation Genetic Diagnosis,
115 EUR. J. OBSTETRICS & GYNECOLOGY & REPROD. BIOLOGY S97 (Supp. 1 2004); New Technology
Predicted, supra note 68.
70. Salvado, Trounson & Cram, supra note 31, at 108. Microarrays are easier to conduct than
FISH and more sensitive, in some cases increasing the resolution to 100-200 kilobases. Wells &
Levy, supra note 29, at 297. The presence of either normal or abnormal genetic variations in a
sample can be detected by allowing the sample DNA to bond with complementary DNA that codes
for the respective variations. Microarrays permit geneticists to test for the presence of numerous
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mutations and abnormalities at the level of the chromosome, gene or even single
nucleotide polymorphism. 71 Geneticists have developed a new technique, array-
based comparative genomic hybridization, to screen for small sequences of DNA
in a manner that will enable them to examine the integrity of all forty-six
chromosomes as well as hundreds of genes from a single embryonic cell. 72 While
this procedure is relatively new and has not been performed clinically in ART,
the future of PGS lies in screening technology that can provide complete
chromosomal information along with significant DNA sequencing information
from one cell in forty-eight hours or less.
The ability to combine chromosomal analysis with specific gene tests will
revolutionize PGS. Couples undergoing PGD to select against embryos affected
with a serious genetic disorder will be able to select from the remaining
unaffected embryos based upon a range of characteristics. While PGD was
initially created for disorders that were guaranteed to develop if the gene was
present,73 PGS will rely much more heavily on detecting genes that increase the
probability that a disorder will develop.
The shift to probability is occurring because the vast majority of human
characteristics or conditions with any genetic component are multigenic and
multifactorial. 74 As scientists' understanding of genetics develops, they will be
able to create statistical models that use the presence of numerous gene variants
to provide a more complete picture of an embryo's probability of developing a
specific disorder or condition.75 This type of genetic modeling could be used to
genetic variants at one time by placing hundreds of complementary sequences of DNA onto the
array and then permitting the sample DNA to bind with its complementary sequences. Salvado,
Trounson & Cram, supra note 31, at 112.
71. Salvado, Trounson & Cram, supra note 31, at 112. A single nucleotide polymorphism
(SNP) is a change in the single nucleotide, the building block of DNA. A single gene will often
have thousands of nucleotides. See Human Genome Project Information, Information,
http://www.ornl.gov/sci/techresources/Human-Genome/publicat/primer/priml'html (last visited
Apr. 18, 2008); Human Genome Project Information, SNP Fact Sheet, http://www.ornl.gov/sci/
techresources/HumanGenome/faq/snps.shtml (last visited Apr. 18, 2008).
72. See Wells & Levy, supra note 29.
73. See BARUCH, KAUFMAN & HUDSON, supra note 28, at 1.
74. See Collins et al., supra note 67, at 840.
75. See, e.g., Marylyn D. Ritchie et al., Optimization of Neural Network Architecture Using
Genetic Programming Improves Detection and Modeling of Gene-Gene Interactions in Studies of
Human Diseases, 4 BMC BIOINFORMATICS 28 (2003), http://www.biomedcentral.com/1471-
2105/4/28; Quanhe Yang et al., Improving the Prediction of Complex Diseases by Testing for
Multiple Disease-Susceptibility Genes, 72 AM. J. HUM. GENETICS 636, 644 (2003). For instance, if
seventeen genes are associated with heart disease, knowledge of the allelic makeup of all seventeen
genes and how much each allele contributes to the development of heart disease could provide
prospective parents with valuable information on the likelihood that a specific embryo would
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provide probability information on all types of genetic traits, as well as to inform
parents regarding the potential impact of certain environmental stimuli.
Improvements in our understanding of gene function will also provide
information on non-disease-related genetic traits, such as height, hair color, skin
color, eye color, and possibly some behavioral characteristics. Geneticists
investigating pigmentation in skin, hair, and eyes are beginning to make
substantial discoveries.76 The genetic determinants of behavior are much more
complex, but scientists may discover genes that govern certain behavioral
characteristics through research into psychiatric disorders and other conditions.77
The future capabilities of PGS are best described by a hypothetical. Imagine
a couple that, because of fertility problems, plans to use IVF. The clinician
harvests fourteen eggs from the prospective mother and fertilizes them with the
prospective father's sperm. Ten of the eggs are successfully fertilized, and eight
of those develop normally to the eight-cell stage. At that point, PGS is used to
screen the eight remaining embryos for various chromosomal and genetic
conditions. Results might indicate that chromosomal defects exist in embryos 1,
3, and 8 that make it unlikely that those embryos would result in a live birth.
Embryo 2 can produce a baby, but the child would have Down syndrome.
Embryo 6 would have cystic fibrosis. Embryos 1, 2, and 8 would carry one copy
of the cystic fibrosis gene, which would not affect them but could result in their
offspring having the disease. Embryos 5 and 7 have twice the normal chance of
developing Alzheimer's disease in older age; embryos I and 7 have double the
normal risk of breast cancer. Embryos 1, 3, 4, and 7 are female; embryos 3, 4,
and 7 would likely be taller than average; embryos 1, 4, and 8 would have blue
eyes.
Physicians are likely to present their patients with charts describing the
characteristics of each of their embryos and offer them genetic counseling
services to ensure that they understand the risks associated with each condition.
At some point, the potential advantages of avoiding disease, limitinig disease
risks, and choosing non-disease traits may make PGS (even with its associated
need for IVF) worthwhile even for fertile couples who are not at any known risk
for children with a serious genetic disease. For many couples, "more information
about the medical status of embryos and pregnancies is likely to be perceived as
preferable," even if it is only probabilities.7 8 While PGS presents prospectiye
couples with numerous potential benefits, it is also poses some significant risks.
In deciding whether to intervene in reproductive aspects of citizens' lives,
develop heart disease. In some cases, this could be as high as 90% or more.
76. See Bastiaens et al., supra note 9; Duffy et al., supra note 9.
77. Ridha Joober, Sarojini Sengupta & Patricia Boksa, Genetics of Developmental Psychiatric
Disorders: Pathways to Discovery, 30 J. PSYCHIATRY & NEUROSCIENCE 349, 351-52 (2005).
78. Malinowski, A Law-Policy Proposal, supra note 20, at 558.
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the government should consider the nature of the people involved and the
potential for government intervention to improve their situation. The people put
at risk by unrestricted PGS use are some of the most vulnerable in American
society: the disabled, the poor, children, the infertile, the stigmatized, and
prospective parents desperate for a healthy child. The government has an
obligation to protect the interests of vulnerable groups in the face of risks put
upon them by the actions of others. For each vulnerable group, extending
government oversight - whether to reduce discrimination, increase access,
mitigate health risks, or provide better information - should reduce the risk of
harm.
II. Is PGS OVERSIGHT NECESSARY?
In order to protect vulnerable groups, the government must first decide how
extensively to intervene into the lives of its citizens. If the government limits the
freedom of individuals to use a technology, it should do so in a principled,
systematic manner.79 The principles the government selects as the foundation of
its regulatory agenda will determine the scope of the potential public policy. As
the regulation of assisted reproductive technologies affects some of the most
important and personal decisions of the citizenry, the government should exercise
caution when deciding whether and how to intervene.
80
A. The Authority of Society over the Individual
In determining the extent to which the government should regulate the use of
PGS by prospective parents, John Stuart Mill's discussion of the limits of the
authority of society over the individual is instructive.81 Mill argues that "[a]s
soon as any part of a person's conduct affects prejudicially the interests of others,
society has jurisdiction over it, and the question whether the general welfare will
or will not be promoted by interfering with it becomes open to discussion."
82
This general principle can be applied to define the boundaries of PGS regulation.
Mill's principle establishes a high threshold for governmental intervention
that protects individual autonomy while not ignoring the interests of other
79. See ALAN BUCHANAN ET AL., FROM CHANCE TO CHOICE: GENETICS AND JUSTICE 4, 15
(2000) (discussing the need to identify basic moral principles to guide public policy, and noting that
"institutional ethical principles ... are most essential for a just and humane society equipped with
robust capabilities for genetic intervention").
80. See Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833, 849 (1992) (holding that "the
Constitution places limits on a State's right to interfere with a person's most basic decisions about
family and parenthood").
81. J.S. MILL, ON LIBERTY 73-91 (Elizabeth Rapaport ed., Hackett Publ'g Co. 1978) (1863).
82. Id. at 73.
HeinOnline -- 8 Yale J. Health Pol'y L. & Ethics 301 2008
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
members of society. Under this approach, the government should intervene only
if the use of PGS threatens unjust harm to either the individuals involved in the
procedure83 or the members of society affected by use of the procedure. The
latter category might include those who do not have access to these technologies
but must compete with those who do; those with diseases and conditions
screened out by PGS who may receive less understanding and support from
society; those who have to pay for others' medical care; and possibly those who
are greatly disturbed by widespread use of these technologies. 84 Mill's
libertarian standard generally opposes government intervention unless it is
absolutely necessary; 85 regulations that would be acceptable under this
standard represent the minimum that the government should do to oversee
PGS. Many would argue that the government should do even more.
Federal and state governments have generally followed Mill's approach in
regulating health care. They have been reluctant to interfere in individual medical
decisions, intervening only when it has been necessary to protect the patient or
society. For patients, the government has acted 1) to require physicians to
provide patients with material information necessary to give informed consent;
86
2) to ensure the competence or safety of the personnel, clinic, hospital, and
laboratory providing medical care; 87 and 3) to eliminate the use of unsafe,
ineffective, or counterfeit drugs.88
When an individual's medical decision could negatively affect others, the
83. This includes both prospective parents and children. The government should intervene to
protect parents from the potential harms caused by information asymmetries common in medical
practice and from unsafe or ineffective health care practices.
84. Mill's original principle would not include "distaste," "outrage," or discomfort to others as
a harm that constitutes grounds for governmental regulation. MILL, supra note 81, at 81-82.
However, in this context, given the passionate nature of the debate over abortion and status of the
embryo in the United States, I have elected to include this as a harm that should warrant
government consideration and possibly intervention, albeit a harm of lesser value than other more
direct harms caused by PGS.
85. See id. at 73-74, 76-77.
86. See Jaime Staples King & Benjamin W. Moulton, Rethinking Informed Consent: The Case
for Shared Medical Decision-Making, 32 AM. J.L. & MED. 429 app. at 493-501 (2006) (listing state
informed consent statutes and relevant cases).
87. 42 U.S.C. § 263a(b) (2000) (requiring all laboratories that solicit or accept materials
derived from the human body for laboratory examination to be certified).
88. 21 U.S.C. § 393(b) (2000) (stating that the mission of the FDA is to ensure the safety and
efficacy of drugs and medical devices). Outside of medical treatment decisions, the government
intervenes in the health care system significantly in its capacity as payor for Medicare and
Medicaid services. As a payor, the government determines which services it will reimburse
physicians for and at what rates. This has a substantial impact on the overall practice of medicine.
See, e.g., PAUL J. FELDSTEIN, HEALTH POLICY ISSUES: AN ECONOMIC PERSPECTIVE 109-13, 115-18,
202-03 (3d ed. 2003).
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government has restricted the individual's autonomy to protect society. States
may use their police power to quarantine individuals or mandate vaccinations in
order to protect the public's health. 89 The government also has the power to
regulate individual medical decisions based on non-health-related social
interests. 90 With respect to reproductive autonomy, the Supreme Court in
Gonzales v. Carhart recognized the right of the federal government to prohibit
the use of a medical procedure, partial-birth abortion, on the basis of social
interests in respecting the life of the unborn and protecting the integrity of
physicians.91 To determine whether intervention is appropriate, the government
must understand the individual and social risks associated with PGS.
B. Risks Associated with PGS
While PGS offers numerous benefits to prospective parents, its unfettered
use threatens harm to both individuals and society. Although many of the known
risks rarely materialize, these harms can be substantial for both the offspring and
the parents, ranging from minor inconveniences to serious physical and mental
disabilities and death. Expanding PGS use also raises social concerns regarding
discrimination, disparities in access, and devaluing the embryo.
1. Risks to Offspring Born via PGS
Risks to offspring born via PGS result from the transfer of multiple
embryos, 92 the ART procedures used to create the embryo, like IVF and ICSI,
and the embryo biopsy.93 Although ART procedures used to give an individual
life cannot be said to harm that individual, unless the life was not worth living,
the risks associated with such procedures are important for physicians, patients,
and the government to consider in making decisions regarding their use.
94
89. See, e.g., Jacobsen v. Massachusetts, 197 U.S. 11 (1905); O'Neil v. State, 32 So. 667 (Ala.
1902); see also Lawrence 0. Gostin, Jeffery P. Koplan & Frank P. Grad, The Law and the Public's
Health: The Foundations, in LAW IN PUBLIC HEALTH PRACTICE 3, 16 (Richard A. Goodman et al.
eds., 2003).
90. See, e.g., Gonzales v. Carhart, 127 S. Ct. 1610, 1617 (2007) (holding that partial-birth
abortion could be regulated for the purposes of "protecting innocent human life from a brutal and
inhumane procedure and protecting the medical community's ethics and reputation").
91. Id.
92. See Klemetti et al., supra note 14, at 1821 (discussing the number of multiple births
resulting from IVF).
93. See Sirpa Soini et al., The Interface Between Assisted Reproductive Technologies and
Genetics, 14 EUR. J. HUM. GENETICS 588, 608-09 (2006).
94. DEREK PARFIT, REASONS AND PERSONS, 358-61 (1984) (describing the "non-identity
problem" as the dilemma that an individual cannot be said to be harmed by a decision that led to his
or her birth, unless the life was not worth living, which can be applied to parental decisions to use
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Parents and clinicians often decide to transfer more than one embryo per
cycle of IVF or PGS to improve success rates.95 This practice increases the
incidence of multiple births from 3% with natural conception to 33% with IVF,96
and as a result, harms the overall health of children born via IVF. 97 In a study
published in Pediatrics, Reija Klemetti and colleagues found that IVF infants
"showed much worse" perinatal health indicators than naturally conceived
children, which was partly explained by multiple gestations 9 8 Klemetti found
that IVF infants were more likely to be born through Cesarean section (35.8% vs.
15.3%), to be born preterm (23.6% vs. 5.5%), to have low birth weight (24% vs.
4.8%), to require treatment in the newborn intensive care unit (23% vs. 8.2%), to
require hospitalization for seven days or more (23.8% vs. 6.4%), and to die
perinatally (1.3% vs. 0.6%) compared to naturally conceived controls.99 Practice
guidelines or regulations limiting the number of embryos that clinicians can
transfer could significantly reduce the incidence of adverse health outcomes
associated with IVF multiple births, albeit at the cost of lowering the percentage
of IVF cycles that result in a live birth.100
ART that risk harm to the resultant child).
95. See Michael Le Page, Fertility Experts Call for One Embryo per IVF Cycle, NEW
SCIENTIST, Oct. 18, 2006, http://www.newscientist.com/channel/sex/dn10326-fertility-experts-call-
for-one-embryo-per-ivf-cycle.html.
96. CTRS. FOR DISEASE CONTROL & PREVENTION, 2004 ASSISTED REPRODUCTIVE TECHNOLOGY
SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY CLINIC REPORTS 22 (2006), available at
http://ftp.cdc.gov/pub/Publications/art/2004ART508.pdf (stating that approximately 33% of all live
births from IVF produced more than one infant (30% twins, 3% triplets or more) compared with
3% incidence in the normal population).
97. Bonduelle et al., supra note 15, at 416-18; Michble Hansen et al., The Risk of Major Birth
Defects After Intracytoplasmic Sperm Injection and In Vitro Fertilization, 346 NEW ENG. J. MED.
725, 727 (2002); Klemetti et al., supra note 14, at 1822 (2006); Soini et al., supra note 93, at 606-
07.
98. Klemetti et al., supra note 14, at 1822. Perinatal health indicators are those surrounding the
time of birth, both before and immediately after. Klemetti et al. found that nearly half of IVF
infants born from multiple births required hospitalization beyond seven days (47.4% vs. 6.4%) and
treatment in the NICU (42.1% vs. 8.2%) compared with naturally conceived infants. The risk of
perinatal death also nearly quadrupled from 0.6% in naturally conceived infants to 2% in IVF
infants from multiple births.
99. Id. at 1822 tbl. 2 (comparing 4559 infants conceived by IVF and 190,398 infants conceived
naturally).
100. The American Society for Reproductive Medicine recently issued practice guidelines that
recommend transferring a limited number of embryos based upon the woman's age and
reproductive history. See Practice Comm., Soc'y for Assisted Reprod. Tech. & Practice Comm.,
Am. Soc'y for Reprod. Med., Guidelines on Number of Embryos Transferred, 86 FERTILITY &
STERILITY S51 (2006). Whether clinicians will abide by the voluntary guidelines remains in
question as transferring fewer embryos reduces the pregnancy success rates of the procedure, which
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However, practice guidelines and regulations limiting the number of
embryos transferred cannot eliminate all of the risks associated with IVF and
ICSI. Studies performed in the last few years have consistently shown that
singleton babies born via IVF and ICSI also have higher rates of mortality,
preterm delivery, congenital malformations, and low birth weight compared to
naturally conceived babies. 10' Likewise, by the age of five, IVF and ICSI
children were more likely to have had a childhood illness and significantly more
likely to have had a surgical operation than naturally conceived children.
10 2
However, the data remain unclear as to what portion of the negative health
outcomes of IVF and ICSI result from the underlying cause of parental infertility,
rather than the ART procedures themselves.'0 3 While the health of IVF and ICSI
children appears to be worse than naturally conceived children, it is not
overwhelmingly so.104 Nonetheless, these risks should be balanced against the
relevant interests in undergoing IVF or ICSI.
In cases of infertility, the government should weigh the above risks against
the parents' interests in having a healthy biological child and against the
is often undesirable for prospective parents and clinicians. Prospective parents likely prefer higher
success rates per cycle, as they often pay for the procedure out of their own pocket and desire a
child sooner rather than later. Clinicians may prefer higher success rates per cycle because clinics
gain reputations based on the ratio of pregnancies and live births per cycle.
101. See Bonduelle et al., supra note 15; Halliday, supra note 14; Hvidtjom et al., supra note
14; Klemetti et al., supra note 14; Mastenbroek et al., supra note 16. But see Tracy Hampton, Panel
Reviews Health Effects Data for Assisted Reproductive Technologies, 292 JAMA 2961, 2961
(2004) (meta-analysis found "evidence generally suggestive of no association" between ART
procedures and serious malformations); I. Ponjaert-Kristoffersen et al., International Collaborative
Study of Intracytoplasmic Sperm Injection-Conceived, In Vitro Fertilization-Conceived, and
Naturally Conceived 5-Year-Old Child Outcomes: Cognitive and Motor Assessments, 115
PEDIATRICS e283 (2005), http://pediatrics.aappublications.org/cgi/reprint/l15/3/e283 (finding no
statistical difference between the cognitive and motor skills of children born via ICSI and naturally
conceived children).
102. Bonduelle et al., supra note 15, at 417.
103. In October 2006, Professor Mary Croughan found that women who had experienced
fertility problems had children with 2.7 times the risk of having autism, mental retardation, cerebral
palsy, seizures and cancer than women without such conditions. Infertility Link to Autism Risk,
BBC NEWS, Oct. 26, 2006, http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/6086824.stm. For autism
alone, Croughan and colleagues found that the risk increased 400% for offspring of patients with
fertility problems. This research leaves open the contribution that procedures such as IVF and ICSI
made to these negative health outcomes. Harms could have resulted from health problems already
present in the parents, from the procedures they used to try to overcome their infertility, or from a
combination of both.
104. See Bonduelle et al., supra note 15, at 415 (stating that "74% of ICSI children and 77% of
IVF children experienced significant childhood illness compared with only 57% of [naturally
conceived] children").
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embryo's interest in being born. Are the risks to the embryo of being born with a
higher risk of a disease or defect so great as to outweigh the benefit of life itself?
The question of whether a child can be harmed by a procedure that gives it life
has been the topic of debate among scholars and in many court cases.10 5 While
legal scholars continue to disagree on this issue, the majority of courts have
refused to hear claims brought by children on the basis that they should not have
been born, so called "wrongful life claims"; 10 6 however, parents have
successfully brought "wrongful birth claims" to recover the cost of raising a
disabled child from physicians for failure to diagnose the disorder or prevent its
occurrence. °7 Currently, the risks of IVF and PGS do not make an individual's
life so miserable as to negate its value, therefore its use for fertility purposes
remains appropriate in those populations where PGS can improve IVF success
rates.108 In contrast, in cases where IVF and PGS are not necessary for the parents
to give birth, the risk to the child from the procedures should be weighed against
the benefits of selecting for a certain characteristic.
More investigation is necessary to determine the full extent and magnitude
105. See, e.g., PARFIT, supra note 94, at 358-61 (describing the "non-identity problem"); Carl H.
Coleman, Conceiving Harm: Disability Discrimination in Assisted Reproductive Technologies, 50
UCLA L. REV. 17, 56 (2002) (stating that it is "possible to object to efforts to bring about the birth
of a child likely to suffer considerably even if the child, once born, would not consider her life a
disadvantage"); Philip G. Peters, Jr., Protecting the Unconceived: Nonexistence, Avoidability, and
Reproductive Technology, 31 AR1z. L. REV. 487, 502-03 (arguing that a miserable life may be
worth continuing, but not worth receiving); John A. Robertson, Procreative Liberty and Harm to
Offspring in Assisted Reproduction, 30 AM. J.L. & MED. 7, 14 (2004) (arguing that if the child's life
is not so miserable as to be wrongful, then the child would have benefited from being born, and the
use of the ART cannot be restricted on the basis of harm to the child).
106. See, eg., Walker ex rel Pizano v. Mart, 790 P.2d 735, 741 (Ariz. 1990) (holding that a
child bringing a "wrongful life" claim had suffered no legally cognizable injury); Kassama v.
Magat, 792 A.2d 1102, 1115-23 (Md. 2002) (noting that twenty-eight other states had rejected
wrongful life claims); Viccaro v. Milunsky, 551 N.E.2d 8, 12 (Mass. 1990) (refusing to recognize a
cause of action for wrongful life). A few jurisdictions will permit wrongful life claims. See, e.g.,
Galvez v. Frields, 107 Cal. Rptr. 2d 50, 57-59 (Cal. Ct. App. 2001) (noting that California
explicitly acknowledges a child's right to bring a wrongful life claim); Harbeson v. Parke-Davis,
Inc. 656 P.2d 483, 495 (Wash. 1983) (reasoning that "a child may maintain an action for wrongful
life").
107. See, e.g., Keel v. Banach, 624 So. 2d 1022, 1026 (Ala. 1993) (recognizing a cause of action
for wrongful birth); Turpin v. Sortini, 643 P.2d 954, 957 (Cal. 1982) (citing a number of cases in
which parents were permitted to recover general damages for the wrongful birth of their children);
Emerson v. Magendatnz, 689 A.2d 409 (R.I. 1997) (recognizing a parent's claim against a
physician after a sterilization procedure failed); Noah, supra note 20, at 638-40.
108. These populations include couples that have experienced repeated miscarriages or
otherwise have a poor prognosis related to chromosomal abnormalities. See Munn& et al., supra
note 37, at 329; Verlinsky et al., supra note 34, at 221.
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of the risks associated with IVF. However, the known risks of IVF alone warrant
regulation of uses outside of infertility to ensure that the benefits of the procedure
outweigh the risks to both mother and offspring. Improved data collection and
research regarding benefits and risks of PGS on the lives of children born
through the technology is needed. Without such information, parents will
continue to make under-informed decisions that may jeopardize the health of
their children.
In addition to the risks from transferring multiple embryos and embryo
creation, couples that use PGS may subject their offspring to additional harm
caused by the embryo biopsy procedure. While the bulk of available evidence
suggests that infants born via PGS have roughly similar health outcomes to those
born via IVF, the question of whether removing cells for genetic testing harms
development still looms over the practice of PGS. 10 9 Harm from the embryo
biopsy was one of the first reasons suggested for the drop in live birth rates from
37% in IVF patients to 25% in IVF patients undergoing PGS as shown in a recent
study from the Netherlands." l0 Other scientists have suggested that imprecise or
unskilled embryo biopsy can substantially harm the embryo, preventing
implantation and development."' In addition, whether the embryo biopsy can
cause developmental and other health problems that may arise later in life
remains unknown, as few children born through PGS have reached puberty.
Some of the risks associated with PGS may also be psychological. The
President's Council on Bioethics expressed concern that even "the present, more
modest, applications of PGD - screening for severe medical conditions,
screening for genetic predispositions for a given disease, elective sex selection,
and selection with an eye to creating a matching tissue donor" treat the child as
merely a "means to the parents' ends."'"12 Under this view, embryo selection
based on genetic traits establishes the child as an instrument of the parents' goals,
as opposed to a gift in and of himself or herself. Jurgen Habermas and Michael
Sandel have argued that this level of parental control limits the sense of freedom
and personal control children born through PGS will have over their lives."
13
However, in the absence of PGS, many parents exercise extensive control over
109. Mastenbroek et al., supra note 16, at 15-17; Verlinsky et al., supra note 28, at 292-94;
Preimplantation Genetic Diagnosis Okayfor Test-Tube Babies, Study Finds, SCIENCE DAILY, June
18, 2007, http://www.sciencedaily.com/releases/2007/06/070616191628.htm.
110. Mastenbroek et al., supra note 16. For further explanation, see supra note 37.
111. Munn6 et al., supra note 37.
112. PRESIDENT'S COUNCIL ON BIOETHICS, REPRODUCTION AND RESPONSIBILITY: THE
REGULATION OF NEW BIOTECHNOLOGIES 95 (2004), available at http://www.bioethics.gov/reports/
reproductionandresponsibility/_pcbe-final-reproduction and-responsibility.pdf [hereinafter
PRESIDENT'S COUNCIL].
113. JURGEN HABERMAS, THE FUTURE OF HUMAN NATURE 75 (2003); MICHAEL J. SANDEL, THE
CASE AGAINST PERFECTION 82-83 (2007).
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their children's lives and use their children as instruments of their own ends.
Psychological research is needed to substantiate the view that PGS would
significantly increase this risk.
While continued research is necessary to better understand the health
implications of PGS for offspring, the government should make efforts in the
present to educate physicians and prospective parents on the known risks to
offspring from IVF and the potential risks associated with embryo biopsy, despite
their uncertain scope and magnitude.
2. Risks to the Prospective Parents
Risks also exist for the prospective parents who engage in PGS. IVF poses
several health risks to women. The hormone stimulation procedures required to
retrieve the eggs can lead to ovarian hyperstimulation, which can result in
nausea, vomiting, shortness of breath, distended abdomen, and hospitalization.'
1 4
The multiple gestations common with IVF also increase maternal risks, such as
pregnancy-induced hypertension, gestational diabetes, and excessive bleeding in
labor and delivery. 15 IVF also doubles the risk of an ectopic pregnancy, which
can necessitate surgery and in rare cases result in death.1 16 Serious concern also
exists about the long-term risks associated with IVF. 117 Some researchers
hypothesize that the hormones included in the ovarian stimulation injections may
increase the risk of breast, ovarian, and endometrial cancer. 118 However, to date
research has found no association between these cancers and IVF use, but more
studies should be performed in the future to confirm these early findings.119
114. See WORKSHOP REPORT, supra note 59, at 17-19; Grainger, Fraizer & Rowland, supra note
59, at S162.
115. See, e.g., Barbara Luke & Morton B. Brown, Contemporary Risks of Maternal Morbidity
and Adverse Outcomes with Increasing Maternal Age and Plurality, 88 FERTILITY & STERILITY
283, 286 (2007). For instance, the risk of pregnancy-induced hypertension doubles from just under
4% in women pregnant with one fetus to just under 8% in those carrying twins and over 11% in
those carrying triplets. Id.
116. Willem M. Ankum, Diagnosing Suspected Ectopic Pregnancy, 321 BRIT. MED. J. 1235,
1235 (2000) (stating that the maternal death rate associated with ectopic pregnancies is estimated to
be 0.3-0.4 per 1000 ectopic pregnancies); Ctrs. for Disease Control & Prevention, Ectopic
Pregnancy - United States, 1990-1992, 27 MORBIDITY & MORTALITY WKLY. REP. 44, 46-48 (1995)
(finding 19.7 ectopic pregnancies out of 1000); Soini et al., supra note 93, at 606 (finding IVF
pregnancies had a 4% chance of being ectopic); Stephen K. Van Den Eeden et al., Ectopic
Pregnancy Rate and Treatment Utilization in a Large Managed Care Organization, 105
OBSTETRICS & GYNECOLOGY 1052, 1052 (2005) (finding a rate of 20.7 ectopic pregnancies per
1000).
117. WORKSHOP REPORT, supra note 59, at 22.
118. Id. at 22-24.
119. Id. at 24-26.
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Clinicians and policymakers frequently overlook the risks to women from
engaging in ART because the women are often willing to accept almost any
personal risk to have a healthy child. Due to the vulnerability of the ART patient
population, the government in conjunction with physicians should develop
practice guidelines designed to reduce the risk of ART. The government should
also help ensure that clinicians inform women of the risks and benefits associated
with IVF, as well as alternatives, such as natural IVF and mild IVF, that may
mitigate these risks.120
In addition to determining the risks to the offspring and the mother,
prospective parents should also consider two additional factors that may impact
the benefit of making a particular genetic selection: the accuracy of the genetic
tests and the complex risk factors associated with embryo selection.12 1 Inaccurate
genetic tests can produce false positives or false negatives, thereby negating the
benefit of the selection.12 Certain features of embryo selection may also result in
parents' selecting for a specific trait and inadvertently also selecting for an
undesired trait. Both factors can easily result in a miscalculation of the benefit
gained by undergoing PGS.
The potential for genetic testing errors creates risk within PGS. These errors
can arise from the limited genetic sample available for PGS, inaccuracy of the
tests themselves, and human laboratory errors. Despite public beliefs to the
contrary, the government conducts very little oversight or regulation of genetic
tests in comparison to other healthcare products. 123 The FDA has not approved
120. Natural IVF, which does not use hormone injections to stimulate the ovaries, but removes
only one egg as the woman ovulates, eliminates the need for stimulation hormones altogether. For
other women who need ovarian stimulation, clinicians have started to successfully use milder doses
of hormones to reduce the negative side effects for women, the costs of IVF, and the risk of
pharmaceutical interference with embryo development. F. Ubaldi et al., Hopes and Facts About
Mild Ovarian Stimulation, 14 REPROD. BIOMEDICINE ONLINE 675, 679 (2007).
121. The risks associated with misdiagnosis and embryo selection are risks to the parents as
opposed to risks to the children born through PGS because any child born as a result of these errors
could not have been born in their absence. A misdiagnosis that caused parents to select an affected
embryo over a non-affected embryo could not be said to have harmed the resultant child, as that
child would not otherwise been born. See PARFIT, supra note 94, at 356-61 (arguing that such an
action cannot be said to harm the resultant child because a different person would have been born
had the error not occurred); Robertson, supra note 105, at 27 (arguing that "if enabling the birth of
children with diseases such as cystic fibrosis, Tay-Sachs, deafness, sickle cell anemia, or
Huntington's disease is ethically problematic, it would have to be on some ground other than harm
to the children themselves").
122. BARUCH, KAUFMAN & HUDSON, supra note 28, at 4.
123. Genetics & Pub. Policy Ctr., Genetic Testing Quality Initiative, http://www.dnapolicy.org/
policy.gt.php (last visited Mar. 30, 2008) (noting the results of a recent study finding that the public
widely believed that the government regulated the quality of genetic tests, and that the government
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genetic tests as safe and effective unless they are sold commercially as test kits,
which rarely occurs. 124 Laboratories conducting genetic tests are not required to
go through any accreditation or approval process outside of the very basic
requirements that the Clinical Laboratory Improvement Amendments of 1988
(CLIA) places on all laboratories. 125 These requirements do not address any of
the specific complexities associated with genetic testing, such as penetrance,
gene-gene interaction, and gene-environment interaction.
126
Devastating errors in PGS practice have occurred as a result. 27 The level of
misdiagnoses in PGS remains largely unknown, but while conducting interviews
with couples that had undergone PGS, members from the Genetics and Public
Policy Center found that the embryos of three of seven women who had become
pregnant following PGS had been misdiagnosed. 128 Due to error rates that are
"not negligible," the Preimplantation Genetic Diagnosis International Society
recommends that all PGS patients undergo prenatal screening during pregnancy,
either through amniocentesis or chorionic villus sampling, to confirm the
diagnosis. 129 In the absence of comprehensive data collection on PGS procedures
and their outcomes, the frequency and impact of misdiagnosis are impossible to
calculate. 
30
More so than in nearly any other area of medical testing, every effort should
be made to ensure the accuracy of the tests and procedures performed for PGS.
Secondary genetic tests cannot be performed to confirm results in the forty-eight
hours required to implant the embryo. Extra DNA is not available if a sample is
should perform this function).
124. Gail H. Javitt, Policy Implications of Genetic Testing: Not Just for Geneticists Anymore, 13
ADVANCES IN CHRONIC KIDNEY DISEASE 178, 179 (2006) (stating that of the more than 900 genetic
disease tests available, test kits are available for only around a dozen).
125. See Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. § 263a (2000); see
also Javitt, supra note 124, at 178.
126. See supra note 19.
127. In one documented case, a couple that already had a child with Fanconi anemia underwent
PGD to select an embryo that was unaffected by Fanconi anemia and was a genetic tissue match for
their sick child. Instead of transferring two unaffected embryos that could serve as cord blood
donors to save the existing child, laboratory error resulted in the transfer of two embryos with the
Fanconi anemia genetic mutation. See, e.g., GENETICS & PUB. POLICY CTR., ISSUE BRIEF ON
OVERSIGHT OF PREIMPLANTATION GENETIC DIAGNOSIS 1 (2006), available at http://www.dnapolicy.
org/images/issuebriefpdfs/Oversight-o fPGD Issue_Brief.pdf.
128. Id.
129. The Preimplantation Genetic Diagnosis International Society (PGDIS): Guidelines for
Good Practice in PGD, 9 REPROD, BIOMEDICINE ONLINE 430, 433 (2004) (stating that "[g]iven that
the error rate after single-cell analysis is not negligible, conventional prenatal diagnosis should be
recommended to confirm and complete the analysis").
130. See GENETICS & PUB. POLICY CTR., supra note 127, at 1.
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lost, contaminated or destroyed. For parents, the risk of misdiagnosis can have
extreme consequences, such as the loss of a young child to a severe genetic
disorder, the loss of a potentially healthy, viable embryo, or being faced with the
difficult decision of whether to carry an affected child to term.
The embryo selection process also generates uncertainties. First, even with
one hundred percent accurate genetic testing, PGS may cause a couple, and quite
frequently an infertile couple, to discard an embryo that would never have
developed the undesired disease or condition. Not all genetic conditions are one
hundred percent penetrant, meaning that having the allele associated with a
disorder or condition may not always result in its physical presentation.'
31
Additional genetic or environmental factors that affect gene expression are often
difficult to identify. Physicians and patients should consider gene penetrance in
weighing the benefits of screening for a certain condition or discarding an
embryo based on a specific result.
Second, our knowledge of the human genome and its functional mechanisms
remains in its infancy. Prior to the completion of the human genome project,
scientists estimated that the human genome contained approximately 100,000
protein-coding genes based upon the breadth of human function. 32 Now that the
project is "essentially 'finished,"' its findings suggest that there are only 20,000
to 25,000 protein-coding genes, indicating that each gene performs substantially
more functions than scientists originally thought.' 33 Permitting parents to select
for or against certain alleles based upon the first function discovered may have
significant consequences, as they may unwittingly screen in certain detrimental
traits or screen out certain positive traits.
This point is illustrated by sickle cell anemia, a recessive genetic disease
with severe health consequences, such as severe pain episodes, strokes, anemia,
kidney damage, and lung blockage.1 34 In families with a high prevalence of sickle
cell anemia, PGS could screen out affected and carrier embryos. Doing so may
result in an evolutionary disadvantage, however, because having only one of the
sickle cell alleles produces no disease, but instead provides malarial resistance.1
35
While malaria is not a major health concern for many Americans, alleles linked
131. Human Genome Project, Evaluating Genetic Tests: Some Considerations,
http://www.oml.gov/sci/techresources/HumanGenome/resource/testeval.shtml (last visited Mar.
30, 2008).
132. Human Genome Project, How Many Genes Are in the Human Genome?,
http://www.ornl.gov/sci/techresources/Human-Genome/faq/genenumber.shtml (last visited Mar.
30, 2008).
133. Id.
134. Ga. Comprehensive Sickle Cell Ctr. at Grady Health Sys., The Sickle Cell Information
Center, http://www.scinfo.org/sicklept.htm (last visited Mar. 30, 2008).
135. Id.
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to other disorders or undesirable characteristics may confer different forms of
evolutionary advantage, which could explain their continued existence in the
gene pool.
Many alleles associated with desirable characteristics may also be
unexpectedly associated with negative ones. For example, a couple may wish to
select alleles associated with red hair and freckled skin, but will discover that this
phenotype also carries a heightened risk of melanoma. 136 Obtaining more data
about the range of harms and benefits associated with a certain allele will be
imperative to enable people to weigh the benefits of screening out the allele
against screening out a potential benefit or screening in a certain detriment.
Along with the benefit of being able to select the genetic traits of one's
children comes the responsibility of taking the opportunity to choose genetic
traits and choosing them correctly. 37 In a world where PGS is more common,
parents may experience personal and social pressure to undergo PGS to select
children based on the presence of desirable traits and to avoid the responsibility
for children born with undesirable traits. 
138
Government intervention could mitigate the above risks to prospective
parents. Efforts to improve the safety and efficacy of PGS procedures, increase
research into the long-term health risks of ART, and disseminate information on
the risks and benefits of PGS could improve the practice of PGS and the ability
of parents to make informed treatment decisions. Specific regulatory objectives
will be discussed in Part IV.
3. Risks to Society
In addition to the risks individuals face from PGS, the government should
consider the impact PGS could have on society as a whole. As use of the
technology increases and the range of genetic tests performed expands, the
effects of PGS will no longer be limited to the individuals who use it or are
created by it. 139 Unregulated, the widespread practice of PGS threatens to
increase health disparities due to lack of access, discrimination, and tensions over
the value of an embryo.
136. L.P. Fernandez et at., MCJR: Three Novel Variants Identified in a Malignant Melanoma
Association Study in the Spanish Population, 28 CARCINOGENESIS 1659, 1659 (2007).
137. SANDEL, supra note 113, at 87.
138. Id. at 88-89 (noting that parents of children with Down syndrome and other genetic
disabilities feel judged or blamed); PRESIDENT'S COUNCIL, supra note 112, at 96.
139. PRESIDENT'S COUNCIL, supra note 112, at 96-98.
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a. Access and Health Disparities
Access to ART, including PGS, is limited both financially and culturally.
40
Financially, PGS is already out of reach for many couples. One cycle of PGS,
including IVF, can cost between $12,500 and $16,000.141 While some insurance
companies have provided coverage for PGD to screen out a serious genetic
disorder, most companies generally do not provide coverage for PGS for
infertility. 42 As DNA microarrays enable parents to screen for multiple genetic
conditions, the price for PGS will only increase.
143
Cultural and educational factors can also inhibit access to PGS. While
income and health insurance are important factors leading to disparities in health
across populations, health care researchers also argue that "much of the answer
has to be found elsewhere."' 144 It remains important to consider that
discriminatory practices, 145 educational inequality, 146 and cultural biases 147 also
140. Mary Crossley, Dimensions of Equality in Regulating Assisted Reproductive Technologies,
9 J. GENDER, RACE & JUST. 273, 278-79 (2005); Eve C. Feinberg et al., Economics May Not
Explain Hispanic Underutilization of Assisted Reproductive Technology Services, 88 FERTILITY &
STERILITY 1439 (2007); Lynn White, Julia McQuillan & Arthur L. Greil, Explaining Disparities in
Treatment Seeking: The Case of Infertility, 85 FERTILITY & STERILITY 853, 855-56 (2006).
141. BARUCH ET AL., supra note 17, at 22 (estimating the cost of IVF to be $10,000-$12,000 and
the cost of PGD to be $2500-$4000); Reproductive Genetics Institute, supra note 63 (charging up
to $5000 for PGD screening plus $2000 for embryo biopsy and other mandatory services).
142. Crossley, supra note 140, at 278. Some states require some form of insurance coverage for
IVF. Seven states - Arkansas, Hawaii, Illinois, Maryland, Massachusetts, New Jersey, and Rhode
Island - have passed legislation mandating that insurance companies provide coverage for IVF.
Three other states - Montana, Ohio and West Virginia - have laws requiring insurance companies
to cover infertility treatments, but not specifically IVF. Finally, California and New York require
coverage for infertility, but specifically exclude coverage for IVF. See Nat'l Conference of State
Legislators, 50 State Summary of State Laws Related to Insurance Coverage for Infertility Therapy,
http://www.ncsl.org/programs/health/50infert.htm (last visited Mar. 30, 2008). To date, no state has
extended mandatory insurance coverage to PGS screening.
143. See, e.g., WORLD HEALTH ORG., GENETICS, GENOMICS AND THE PATENTING OF DNA:
REVIEW OF THE POTENTIAL IMPLICATIONS FOR HEALTH IN DEVELOPING COUNTRIES 13-14 (2005),
available at http://www.who.int/genomics/FullReport.pdf (discussing the restrictive licensing
practices of Myriad Genetics and high costs of tests for the BRCA I and BRCA2 genes, which are
associated with breast, ovarian, and prostate cancer).
144. White, McQuillan & Greil, supra note 140, at 855; see also Feinberg et al., supra note 140,
at 1439-41.
145. Michelle van Ryn & Jane Burke, The Effect of Patient Race and Socio-Economic Status on
Physicians'Perceptions of Patients. 50 SOCIAL SCI. & MED. 813, 813-17 (2000).
146. Tarun Jain & Mark D. Hornstein, Disparities in Access to Infertility Services in a State
with Mandated Insurance Coverage, 84 FERTILITY & STERILITY 222 (2005).
147. Feinberg et al., supra note 140, at 1441.
HeinOnline -- 8 Yale J. Health Pol'y L. & Ethics 313 2008
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
create significant barriers to care. In Massachusetts, which mandates insurance
coverage for IVF services, researchers found that Hispanic/Latino women used
IVF significantly less than expected, based on population demographics, while
Chinese and other Asian/Pacific Islanders used IVF significantly more than
expected. 148 Some of this disparity may result from reduced access to health
insurance amongst Hispanic/Latino women. 149 However, disparities in use by
level of education were much more striking. None of the infertility patients
studied had less than a high school education, compared with 15.1% of the state
population. 150 Likewise, almost half (49.6%) of the patients had advanced
degrees, compared with 12.4% in the state.15 1 Other researchers have
corroborated these results by finding that among individuals in the military health
care system, who have relatively equal access to care and higher education rates
than the average population, Hispanics were still strongly underrepresented
among ART patients despite similar levels of infertility.
1 52
Inequalities in access can increase both health and socioeconomic
disparities. Health disparities between socio-economic groups often result in
disparities in educational, occupational, and income opportunities, which can in
turn further exacerbate existing inequalities. 153 Unregulated PGS use has the
148. Jain & Hornstein, supra note 146.
149. The Massachusetts mandate requires insurance companies that provide pregnancy coverage
to also cover medically necessary infertility diagnosis and treatment, which would include IVF.
MASS. GEN. LAWS ch. 175, § 47H (1998). However, the mandate does not provide access to
infertility treatments to women who do not have any insurance coverage at all. Therefore, the
disparity may result from a lack of insurance coverage in general amongst Latino/Hispanic women,
as opposed to a reluctance to use the technology.
150. Jain & Hornstein, supra note 146, at 222.
151. Id.
152. Feinberg et al., supra note 140, at 1439. The authors examined the use of ART services at
Walter Reed Medical Center within the military health care system, which closely resembles an
equal-access-to-care model. In the Department of Defense, only 6.5% of the Hispanic population
did not graduate from high school, compared with 36.4% of the general U.S. Hispanic population.
Hispanics represented 9% of the Department of Defense population, but only 4% of the ART
population at Walter Reed. The authors concluded that this result is "markedly less than expected if
use was primarily driven by cost," Id. at 1440.
153. Nancy E. Adler & Katherine Newman, Socioeconomic Disparities in Health: Pathways
and Policies, 21 HEALTH AFF. 60 passim (2002). The link between disparities in socioeconomic
status and disparities in health status is established in the medical literature, as is the severity of
health disparities within the U.S. health care system. U.S. DEP'T HEALTH & HUMAN SERVS.,
HEALTHY PEOPLE 2010: UNDERSTANDING AND IMPROVING HEALTH 2, 11-16 (2000), available at
http://www.healthypeople.gov/document/pdf/uih/20]0uih.pdf (identifying eliminating health
disparities as one of two major goals for improving the health of the nation); Ernest Moy, Elizabeth
Dayton & Carolyn M. Clancy, Compiling the Evidence: The National Healthcare Disparities
Reports, 24 HEALTH AFF. 376, 376 (2005).
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potential to increase health disparities across a number of medical conditions.
Prospective parents undergoing PGS will have every incentive to screen embryos
for genes linked to known health conditions. Doing so creates two health
benefits: Their offspring will likely have fewer harmful genetic health conditions,
and the parents will be aware of additional disease susceptibilities. This advance
awareness will enable parents to better address the future needs of their child and
possibly to mitigate or eliminate the effects of the genetic disease.
Since wealthier members of society already receive better health care and
numerous other benefits, it is reasonable to question whether the advantages
provided by PGS raise any additional cause for government intervention to
alleviate health disparities. Two factors differentiate benefits provided via PGS
from other health benefits derived by wealth after birth. First, all subsequent
generations will benefit from selection against disease genes, disease
susceptibility, or certain genetic conditions. Not only will the individual be
advantaged, but this advantage will most likely extend to his or her immediate
descendants. While other advantages, like wealth and opportunity, can be passed
down to children, genetic selection offers this kind of advantage to a greater
degree and with greater certainty. Individuals with a parent that has an autosomal
dominant disorder, like Huntington's disease, have a 50% chance of developing
the disease.1 54 PGD offers parents the opportunity to minimize this worry for
their children and their children's descendants.1 55 Second, selection against
diseases and disease susceptibility prior to implantation eliminates any suffering
or medical treatment associated with a disorder. Often wealthy individuals can
obtain better treatment or care, but many diseases are incurable. For instance,
selecting against genes that have been linked to an increased risk of Alzheimer's
disease1 56 provides an advantage that cannot be obtained by any amount of
money for treatment. Those lacking access to PGS will not be able to obtain
these benefits. Not only will the burden of disease be placed on those least able to
afford care, but it will also be placed on those least able to lobby for research and
treatments. Over time, the shifts in the burden of disease will further exacerbate
health disparities.
154. Individuals with an autosomal dominant disorder will have the disease if they have one
allele associated with the disorder, as opposed to autosomal recessive disorders, which require
individuals to have two disease alleles to have the disease. Children of individuals with autosomal
dominant disorders have a 50% chance of having the disease. Medline Plus, Autosomal Dominant,
http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm (last visited Mar. 30, 2008).
155. While the children could marry an individual with Huntington's disease and then have this
concern arise again, being able to eliminate the immediate risk and worry is highly valuable.
156. See Harrington et al., supra note 3.
HeinOnline -- 8 Yale J. Health Pol'y L. & Ethics 315 2008
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
b. Eugenics and the Impact on Individuals Living with Disabilities
The government should also consider whether individuals' use of PGS
directly harms other members of society. In many ways, PGS is the technological
manifestation of the early twentieth-century eugenicists' goal to "improve the
human condition through genetic selection."'' 57 The seductive nature of this goal
should not be underestimated. In the absence of genetic selection technology,
more than thirty U.S. states enacted involuntary eugenic sterilization laws, which
resulted in the forced sterilization of over 60,000 Americans deemed "unfit" to
procreate during the twentieth century. 58 Although the U.S. government is
unlikely to require individuals to undergo PGS, we should not ignore the
argument claiming that "through ART, the genetics revolution, and carte blanche
procreative liberty, we could do unto ourselves via the collective impact of
individual decision-making what governments have imposed in the past in the
name of bettering the human condition."
'' 59
A number of legal and ethical scholars have argued that in the absence of
governmental regulation and enforcement, individual eugenic practices to select
desirable genetic traits, such as PGS, cease to be morally problematic. 6 ' Judith
Daar has noted that in a diverse society like the United States, "concerns about
eugenics must be viewed from a perspective of 'individual-relativism,"' such that
"one parent's idea of a 'good birth' may be a disappointment, or worse, for
another parent."' 61 Other liberal pluralists argue that while most parents will want
to improve the overall health and well-being of their children, their ideas of how
to do so are likely to differ significantly. 62 This argument has merit in that multi-
use PGS will provide parents with significantly more choice over the types of
characteristics their offspring possess. In contrast to state eugenic policies of the
past, individual embryo selections do not violate others' reproductive rights or
157. Malinowski, Choosing, supra note 20, at 204; see also Judith F. Daar, ARTand the Search
for Perfectionism: On Selecting Gender, Genes and Gametes, 9 GENDER, RACE & JUST. 241, 260-
62 (2005).
158. Daar, supra note 157, at 261.
159. Malinowski, Choosing, supra note 20, at 204; see also BUCHANAN ET AL., supra note 79, at
177.
160. BUCHANAN ET AL., supra note 79, at 27-60, 156-91, 304-45; ROBERT NOZICK, ANARCHY,
STATE AND UTOPIA 315 (1974); Nicholas Agar, Liberal Eugenics, 12 PUB. AFF. QUART. 137 (1998);
Daar, supra note 157, at 260-66.
161. Daar, supra note 157, at 265, 271-72 (arguing that "both parents and children can be
harmed if a parent is denied the opportunity to select to birth a child" possessing a much desired
trait, such as gender).
162. This notion of liberal pluralism and autonomy has been discussed in greater depth
elsewhere. See, e.g., BUCHANAN ET AL., supra note 79, at 176-79; SANDEL, supra note 113, at 75-
83; Agar, supra note 160, at 137.
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personal autonomy, thereby mitigating some of the social risk associated with
reproductive genetic selection.
However, the liberal eugenics argument fails to address how PGS affects the
lives of individuals with the undesired conditions. In a recent survey, 81% of
Americans believed that PGS could lead to further discrimination against the
disabled. 163 A subsection of the disability community, known as the
Expressivists, has argued that the use of preimplantation and prenatal genetic
tests to select for certain traits sends a hurtful message to people with those
traits. 164 Disability activist Marsha Saxton has commented that this message
represents "the greatest insult: some of us are 'too flawed' in our very DNA to
exist; we are unworthy of being born." '1 65 While the desire to bring a child into
the world without seriously limited capabilities does not imply a belief that
individuals with those disabilities should not exist, policymakers should be aware
of these concerns and be prepared to address them.
1 66
Governments seeking to address these concerns face a daunting task.
Permitting parents to discard embryos with "undesirable" genetic traits and
conditions without any government oversight appears to sanction overtly eugenic
practices. In this vein, the President's Council on Bioethics has argued that
unregulated PGS risks "normalizing the idea that a child's particular genetic
makeup is quite properly a province of parental reproductive choice, or the idea
that entrance into the world depends on meeting certain genetic criteria."
161
Alternatively, Adrienne Asch has spoken out against any regulatory attempt at
delineating which genetic tests are appropriate for physicians to offer for
reproductive purposes. 168 By permitting individuals to select against some traits,
but refusing to let people select against other traits, Asch argues that the
163. ANDREA KALFOGLOU ET AL., GENETICS & PUB. POLICY CTR., REPRODUCTIVE GENETIC
TESTING: WHAT AMERICA THINKS 36 fig. 6.1 (2004), available at http://www.dnapolicy.org/
images/reportpdfs/ReproGenTestAmericaThinks.pdf (surveying a nationally representative sample
of 4834 Americans).
164. Erik Parens & Adrienne Asch, The Disability Rights Critique of Prenatal Genetic Testing:
Reflections and Recommendations, in PRENATAL TESTING AND DISABILITY RIGHTS 3, 13-14 (Erik
Parens & Adrienne Asch eds., 2000). Adrienne Asch has specified that the message offends
because it permits a single trait to stand in for the whole person, and in doing so, implies that it is
unnecessary to learn about the rest of that individual. Id. at 13 (citing Adrienne Asch, Why I
Haven't Changed My Mind About Prenatal Diagnosis: Reflections and Refinements, in PRENATAL
TESTING AND DISABILITY RIGHTS 234, 235-36 (Erik Parens & Adrienne Asch, eds., 2000)).
165. Marsha Saxton, Disability Rights and Selective Abortion, in ABORTION WARS: A HALF
CENTURY STRUGGLE, 1950-2000, at 391 (Rickie Solinger ed., 1998).
166. BUCHANAN ET AL., supra note 79, at 274.
167. PRESIDENT'S COUNCIL, supra note 112, at 95.
168. Adrienne Asch, Disability Equality and Prenatal Testing: Contradictory or Compatible?,
30 FLA. ST. U. L. REV. 315, 338-39 (2003).
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government makes a determination that some lives are valued and some lives are
not, which "will surely exacerbate the discrimination and stigmatization of future
children with the listed conditions."'' 69 However, passing regulation to limit the
use of PGS to certain disorders and traits does not necessitate the inference that
the government does not value the lives of its existing citizens with those
disorders. 170 Regulation to ensure resources and protection for individuals with
disabilities should accompany regulation for PGS.
Governments that have examined issues relating to eugenics and
discrimination arising from PGS have taken a range of approaches. Germany, 171
Switzerland, 172 Austria, 17 3 and Italy 74 have all passed legislation banning the
practice of PGS entirely, ostensibly to avoid any implications of eugenic
practices. Countries like Canada 175 and the United Kingdom 76 have established
administrative agencies to review and regulate PGS. The Japanese government
has not passed legislation limiting PGS, but the Japanese Society of Obstetricians
and Gynecologists enacted a strict licensing system that carefully considers the
potential effect of a specific use of PGS on disabled members of society before
permitting a clinic to use PGS for that indication. 77 To date, use of PGS has been
extremely limited in Japan. 178
The U.S. government should not ignore the ability of thousands of individual
reproductive decisions to increase discrimination against individuals with
169. Id. at 339.
170. BUCHANAN ET AL., supra note 79, at 278.
171. Gesetz zum Shutz von Embryonen [Act for Protection of Embryos], Dec. 19, 1990, BGBI.
I, 69 at 2746 (F.R.G); see also Henning M. Beier & Jacques 0. Beckman, German Embryo
Protection Act (October 24, 1990), 6 HUM. REPROD. 605, 605-06 (1991).
172. Bundesgesetz iiber die medizinisch unterstitzte Fortpflanzung [FMedG] [Federal Law on
Assisted Reproduction] Dec. 18, 1998, Die Bundesverslammiung der Schweizerischen
Eidgenossenschaft, art. 24, 1-2 (Switz.); see also Bartha M. Knoppers & Rosario M. Isasi,
Regulatory Approaches to Reproductive Genetic Testing, 19 HUM. REPROD. 2695, 2695 (2004).
173. Gentechnikgesetz - GTG und Anderung des Produkthaftungsgesetzes [The Austrian Gene
Technology Act] Bundesgesetzblatt [BGB1] No. 510/1994 (Austria); see also Knoppers & Isasi,
supra note 172, at 2695.
174. Norme in material di Procreazione Medicalmente Assistita [Medically Assisted
Reproduction Law]. Racc. Uff., Presidential Decree, Feb. 19, 2004, Feb. 24, 2004, No. 4 (Italy).
175. Assisted Human Reproduction Act, 2004 S.C, ch. 2 (Can.) (establishing Assisted Human
Reproduction Canada (AHRC) a federal regulatory agency to oversee the use of AHR in Canada);
see also Health Canada, Assisted Human Reproduction Canada, www.hc-sc.gc.ca/hl-
vs/reprod/agenc/index e.html (last visited Mar. 30, 2008).
176. Human Fertilisation and Embryology Act, 1990, c. 37, § 5 (U.K.).
177. See M. Sugiura-Ogasawara, Reply to: Preimplantation Genetic Diagnosis for
Translocations, 21 HUM. REPROD. 840 (2006).
178. See Santiago Munn&, Preimplantation Diagnosis for Translocation, 21 HUM. REPROD. 839
(2006).
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negatively perceived genetic conditions. While the Americans with Disabilities
Act 179 and the Civil Rights Act180 provide legal protection for some individuals
that may face increased discrimination as a result of widespread PGS use, future
advances in genetic testing may result in discrimination against many other
individuals with unprotected conditions or characteristics, such as sexual
preference. 8 1 In instances where there is direct evidence of harm to a population,
and where anti-discrimination laws are absent or inadequate to reduce the
discriminatory impact, the government should limit parents' ability to use PGS
for the related condition.
c. Respecting and Protecting Potential Human Life
The government should also consider the sentiments of those individuals
who will be outraged by any procedure that permits prospective parents to
discard embryos. Many religious individuals oppose the use of IVF and PGS for
any purpose. 182 As the reasons for discarding embryos become less about
avoiding severe disorders or infertility and more about selecting for desirable
genetic characteristics, many other members of the population may join the
opposition. 183 This opposition may stem in part from the belief that discarding
embryos for treatable medical conditions, disorders with mild symptoms, and
non-medical traits does not account for the embryos' moral worth.
184
In Gonzales v. Carhart, the Supreme Court recently reaffirmed the state's
ability to regulate reproductive medicine in an effort to express its "profound
179. Americans with Disabilities Act of 1990, Pub. L. No. 101-336, 104 Stat. 327 (codified at
42 U.S.C. §§ 12101-12213 (2000)).
180. Civil Rights Act of 1964, Pub. L. No. 88-352, 78 Stat. 241 (codified as amended in
scattered sections of 5, 28, 42 U.S.C.).
181. Americans with Disabilities Act of 1990, Pub. L. No. 101-336, 104 Stat. 327, 376 (codified
at 42 U.S.C. § 12211 (2000)) (specifically stating that "homosexuality and bisexuality are not
impairments and as such are not disabilities"); Desantis v. Pacific Tel. & Tel., 608 F.2d 327 (9th
Cir. 1979) (holding generally that Title VII of the Civil Rights Act did not prohibit discrimination
on the basis of sexual orientation); see also Pekka Santtila et al., Potential for Homosexual
Response Is Prevalent and Genetic, 77 BIOLOGICAL PSYCHOL. 102, 102-05 (2008).
182. See, e.g., Mo Woltering, The Clone Wars: Have We Surrendered Donum Vitae?, SEQUELA,
www.rc.net/org/humanfamily/clonewars.html (last visited Mar. 30, 2008) (arguing against the use
of IVF for any purpose).
183. KALFOGLOU ET AL., supra note 163, at 27 (finding that individuals' approval of PGD use
decreased as the severity of the conditions involved moved from fatal childhood disorders to
selection of traits).
184. Id. at 26-27 (finding that individuals' approval of PGD for less severe genetic conditions
was somewhat, but not entirely related to their belief in the moral status of the embryo, and that
many people gave the embryo an "intermediate" status between person and non-person).
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respect for the life of the unborn." 85 The Court granted the state the right to
promote respect for fetal life both before and after viability.' 86 The Court based
this finding, however, on the notion that "a fetus is a living organism while in the
womb, whether or not it is viable outside the womb."' 87 In Planned Parenthood
of Southeastern Pennsylvania v. Casey, the Supreme Court held that the state
could "from the outset. . . show its concern for the life of the unborn."' 88 While it
has not been settled that the government's interest in protecting the unborn
extends to embryos outside a mother's body, given the language in Carhart and
Casey, and the prohibition on federal funding for embryo research, the
government's ability to restrict some uses of PGS in an effort to demonstrate
respect for the unborn seems probable enough to warrant further consideration.
89
The question is how to weigh society's interests in the life of the unborn
against the interests of the prospective parents. In examining similar questions
relating to embryo experimentation while on the Human Embryo Research Panel,
Alta Charo recommended that the interests of those opposed to embryo research
on moral grounds be considered in terms of the harm directly caused to them by
embryo research.' 90 Such an approach can be used to weigh societal objections to
PGS based on the status of the embryo. The government should consider the
following: 1) How strongly felt are the objections?; 2) Does the practice cause
any form of physical, financial or emotional harm to the individuals?; 3) Are
there structural obstacles that prevent individuals opposing the use from
politically expressing their views?; and 4) Would their opposition deny
constitutional or international human rights to others?' 9' Since individuals
opposing IVF and PGS will not be forced to engage in or conduct the procedures,
their harms will be limited. This analysis would grant little weight to third-party
interests when compared with using PGS to select against a serious disorder, but
in cases of negligible parental benefit in selecting for a particular gene, such as
eye or hair color, strong public opposition may warrant government restriction of
the procedure on grounds that the practice of discarding embryos for less
significant reasons harms others in society. Such an analysis protects individual
reproductive autonomy, but acknowledges the moral opposition to embryo
destruction in instances where an individual uses PGS to screen out traits that do
185. Gonzales v. Carhart, 127 S. Ct. 1610, 1615 (2007) (quoting Planned Parenthood of Se. Pa.
v. Casey, 505 U.S. 833, 877 (1992)).
186. Id. at 1627.
187. Id.
188. Casey, 505 U.S. at 869.
189. A more complete explication of the constitutional limitations on regulation of PGS will be
provided in Part Ill.
190. See R. Alta Charo, The Hunting of the Snark: The Moral Status of Embryos, Right-to-
Lifers, and Third World Women, 6 STAN. L. & POL'Y REV. 11, 20-21 (1995).
191. Id. at 21.
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not trigger reproductive liberty protections. While establishing the right balance
between reproductive liberty and moral opposition to embryo destruction will
remain a thorny area of law, attempting to negotiate a middle ground will prove
safer than a laissez faire approach and more palatable than a highly precautionary
approach.
While recent advances in ART pose significant regulatory challenges, the
risks to both individuals and society are sufficiently credible to require
government intervention. As discussed above, governments in most of the
developed world have heavily regulated ART, including PGS and PGD. 92 In
contrast, federal and state governments in the United States have neglected to
regulate PGS.
C. Why Has the United States Not Regulated PGS?
One of the main reasons the United States has not regulated PGS is because
American politicians do not find it politically advantageous. The lack of political
interest has occurred for three reasons: 1) few studies have demonstrated harm to
children from PGS; 2) the current technological limitations of PGS have
restricted both patient demand and the frequency of its use for controversial
purposes; and 3) PGS regulation is politically divisive. As a result, politicians
have effectively tabled the issue until a significant harm or risk demands political
action.
Scientific research is just beginning to reveal some of the health risks
associated with IVF and PGS. This research is time-consuming, and funding is
scarce. Examining the health outcomes of children born via ART requires
gathering data before the pregnancy and through many years into childhood. To
determine the long-term risks, studies will need to continue from before
pregnancy well into adulthood.
Another difficulty is that, since the 1970s, the federal government has either
greatly limited or banned the use of federal funds for embryo and fetal
research.193 The Dickey-Wicker Amendment currently prevents the use of federal
funds for any activity that involves "the creation of a human embryo or embryos
for research purposes; or ... research in which human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of injury or death greater
192. See Knoppers & Isasi, supra note 172, at 2695.
193. PRESIDENT'S COUNCIL, supra note 112, at 127-31. The restrictions began with a prohibition
on using federal funds to conduct research on IVF without approval from the Ethics Advisory
Board (EAB). In 1979, the EAB attempted to authorize IVF research under certain conditions, but
its recommendation was not accepted by the Department of Health, Education and Welfare. The
EAB was disbanded shortly thereafter in 1980, leaving a de facto moratorium on the use of federal
funds for IVF research. Id. at 127-28.
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than that allowed for research on fetuses in utero under 45 [C.F.R. §]
46.208(a)(2) or 42 U.S.C. [§] 289g(b)."' 94 Since PGS research entails the
possibility of injuring, destroying, and discarding human embryos, it will likely
run afoul of the Dickey-Wicker Amendment.1
95
The absence of federal research funding has pushed reproductive genetics
out of the laboratory and into medical practice. Advances in reproductive
technology, such as PGS, have been widely achieved on the basis of theory-
driven rather than data-driven hypotheses, 196 given the lack of funds for research
and the absence of legislation that requires safety and efficacy research prior to
clinical use. As a result, couples often have to make treatment decisions with
little evidence of safety and efficacy, and policymakers have little data to suggest
a need for regulation.
The lack of PGS oversight is also due in part to the relative seriousness of
current PGS indications and the small number of procedures performed each
year. The small patient population and the current limitations of the technology
largely have tempered concerns that PGS might be used by many people to
screen for a wide range of medical and non-medical conditions. John A.
Robertson, one of the field's most prominent legal scholars, has argued that it is
"highly unlikely that many traits would be controlled by genes that could be
easily tested in embryos"' 97 due to the fact that most genetic conditions result
from interactions between multiple genes and between the genes and the
environment. Leading scientists, policymakers, and scholars have echoed
Robertson's sentiment that the technological limitations associated with PGD
will prevent the dystopias predicted by many ethicists and science fiction authors
related to "designer babies."' 98 Armed with reassurance that PGS is likely to have
little social impact, politicians have remained reluctant to act. This view ignores
the ability of recent technological advances to expand the power of PGS to
screen for numerous genetic loci at one time.
Finally, politicians have been especially hesitant to consider regulating PGS
because it requires consideration of the status of the embryo. Given the extreme
divide in the United States regarding abortion, reaching consensus on the status
194. Balanced Budget Repayment Act of 1996, Pub. L. No. 104-99 sec. 128, 110 Stat. 26, 34.
195. Jacques Cohen & Santiago Munn6, Letter to the Editor, 20 HuM. REPROD. 2363, 2364
(2005) (stating that evidence suggests that removing two cells from cleaved embryos can harm the
embryo beyond repair).
196. John A. Collins, Preimplantation Genetic Screening in Older Mothers, 357 NEw ENG. J.
MED. 61, 61-62 (2007).
197. John A. Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. & MED. 439,
466 (2003).
198. PRESIDENT'S COUNCIL, supra note 112, at 94-97 (2004); see also FRANCIs FUKUYAMA, OUR
POSTHUMAN FUTURE: CONSEQUENCES OF THE BIOTECHNOLOGY REVOLUTION 4-10 (2002)
(describing the dystopia of future PGS use).
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of the embryo appears impossible. 99 Political debate over embryo creation and
destruction often causes people to retreat to their firmly entrenched positions on
abortion, which contributes significantly to the regulatory stalemate with respect
to ART in the United States.200
Despite this reluctance on the part of politicians, the government no longer
has the luxury of delaying consideration of regulation and oversight °. 0 PGS will
soon offer parents the opportunity to screen embryos for hundreds of genetic and
chromosomal characteristics. The development of PGS will expand the demand
for the procedure and its use for controversial ends, in turn creating new
individual and social risks.20 2 The government should put in the political
infrastructure to balance the potential benefits to parents of unrestricted use
against the probability and severity of the risks associated with PGS.
III. WHO SHOULD OVERSEE PGS?
Once the government decides that regulation is appropriate, the next
challenge is to determine who should regulate. Deciding what type of body
should oversee PGS helps to determine the scope and strength of the possible
oversight. In the last five years, medical, legal, and ethical scholars have
proposed that a variety of entities oversee ART and PGS, including 1)
professional societies, 2) state agencies, 3) existing federal agencies, or 4) a new
federal agency. 20 3 While oversight by each of these entities has benefits, the
199. See Charo, supra note 190, at 27 (describing the search for consensus on the status of the
embryo as being "as doomed as the hunting of the illusive snark").
200. The difficulty of passing legislation relating to ART and the appropriate uses of embryos is
exemplified by the failure of Congress to pass a bill prohibiting reproductive cloning, despite
general consensus that it should be illegal. See FUKUYAMA & FURGER, supra note 20, at 129-31,
243 (2006) (chronicling the numerous failed attempts to pass a prohibition on human cloning in the
House and Senate). While the Human Cloning Prohibition Acts of 2001 and 2003 both passed the
House, no prohibition on cloning has passed the Senate. See Human Cloning Prohibition Act, H.R.
534, 108th Cong. (2003); Human Cloning Prohibition Act, H.R. 2505, 107th Cong. (2001). To
date, no federal prohibition on reproductive cloning exists.
201. See Malinowski, Choosing, supra note 20, at 205 ("Arguably, there is a moral imperative
to not assume the luxury of time.").
202. Cf Mastenbroek, supra note 16, at 13 (demonstrating that PGS use was associated with
reduced rates of ongoing pregnancy in women of advanced maternal age when compared to
traditional IVF alone). While the findings of Mastenbroek et al. may reduce the immediate demand
for PGS among women of advanced maternal age, many of the reasons the team suggested for the
difference in rates of ongoing pregnancy resulted from technological limitations, which may be
overcome. Id. at 16. In addition, other researchers have challenged these findings due to the study's
low embryo biopsy success rates. See PGD Pioneers, supra note 37.
203. See, e.g., FUKUYAMA & FURGER, supra note 20, at 14-23 (proposing an independent federal
agency to address human biotechnologies and ART); Malinowski, A Law-Policy Proposal, supra
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creation of a new federal agency to license and monitor ART practice is the most
promising approach.
A. Professional Societies
Medical and professional societies, such as the American Society of
Reproductive Medicine (ASRM) and the Society for Assisted Reproductive
Technology (SART), offer one avenue for oversight of PGS.2 °4  These
organizations, formed by members from a particular medical field or specialty,
typically offer educational services for members and develop guidelines on
appropriate clinical practice.2 °5 Some consider professional societies to be
capable of providing "more nuanced oversight" than would be possible through
legislation. Moreover, some health care providers who oppose government
interference have argued that choices regarding reproductive technologies should
remain a joint matter for doctors and patients. 207
SART is the primary professional society for physicians that perform
ART. 20 8 It performs four main functions to assist its members - data collection
and dissemination, development of practice guidelines and recommendations,
note 20, at 566 (arguing that the United States should create a regulatory system based on existing
federal regulatory schemes); Noah, supra note 20, at 607 (suggesting that the FDA might consider
reviewing their approval of fertility drugs); Norton, supra note 20, at 1642-50 (suggesting that
Congress and state legislatures should ban nontherapeutic PGS); Parens & Knowles, supra note 20,
at S18-21 (suggesting the creation of a federal Reprogenetics Technolgies Board similar to the
United Kingdom's HFEA); Rosato, supra note 20, at 79-95 (proposing a "double-decker" approach
to state and federal ART regulation); Joe Leigh Simpson, Robert W. Rebar & Sandra Ann Carson,
Professional Self-Regulation for Preimplantation Genetic Diagnosis: Experience of the American
Society for Reproductive Medicine and Other Professional Societies, 85 FERTILITY & STERILITY
1653 (2006) (supporting professional society regulation); Model Assisted Reproductive Technology
Act, 9 J. GENDER, RACE & JUST. 55 (2005-2006) (proposing that states oversee the practice of
ART).
204. See Simpson, Rebar & Carson, supra note 203, at 1653 (listing ASRM, SART, the
American College of Obstetricians and Gynecologists, the American College of Medical
Geneticists, the European Society of Human Reproduction and Embryology, and the
Preimplantation Genetic Diagnosis International Society as professional societies that have a stake
in the regulation of PGS).
205. BARUCH ET AL., supra note 17, at 9. For a list of ASRM and SART guidelines and practice
standards issued on ART, see Malinowski, Choosing, supra note 20, at 185-87.
206. See Simpson, Rebar & Carson, supra note 203, at 1653.
207. Andrea L. Kalfoglou et al., Opinions About New Reproductive Genetic Technologies:
Hopes and Fears for Our Genetic Futures, 83 FERTILITY & STERILITY 1612, 1612 (2005).
208. See Soc'y for Assisted Reprod. Tech., Welcome to SART, http://www.sart.org (last visited
Mar. 30, 2008).
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governmental interaction, and quality assurance within ART.2 °9 SART requires
its members to have their embryo laboratories accredited and submit data on
annual success rates to the Centers for Disease Control and Prevention (CDC) in
accordance with the Fertility Clinic Success Rate and Certification Act of 1992
(FCSRCA). 1 ° ASRM is closely affiliated with SART and performs many of the
same political and advisory functions, but also has members that focus on other
types of reproductive medicine.21 1
While medical societies currently play a lead role in ART oversight,2 12 their
ability to monitor, evaluate, and regulate PGS is insufficient to protect vulnerable
groups from harm.2 13 The practice guidelines issued by medical societies are
voluntary and unenforceable. 214 Medical societies do not have the ability to
prosecute members for non-compliance; all they can do is revoke a clinic's
membership. 215 SART membership is not required to operate an ART clinic or to
provide PGS. Given the substantial demand for ART services, the threat of
membership loss has not served as a sufficient deterrent to force compliance with
guidelines.2 16 Despite ASRM's Ethics Committee's strong recommendations
against using PGS solely for the purposes of non-medical sex selection,2 1 7 the
Genetics and Public Policy Center survey found that 39% of clinics were willing
to provide non-medical sex selection in the absence of another reason to undergo
PGS, and just under 10% of the PGS procedures performed in the surveyed
clinics were for non-medical sex selection.218 As the market for PGS expands and
209. See Soc'y for Assisted Reprod. Tech., What is SART?,
http://www.sart.org/WhatlsSART.html (last visited Mar. 30, 2008).
210. Id.; see also Fertility Clinic Success Rate and Certification Act of 1992, Pub. L. No. 102-
493, 106 Stat. 3146 (codified at 42 U.S.C. § 263a-1 to 263a-7 (2000)).
211. See Am. Soc'y for Reprod. Med., http://www.asrm.org (last visited Mar. 30, 2008). ASRM
also publishes the journal Fertility & Sterility.
212. See Simpson, Rebar & Carson, supra note 203, at 1653 (noting that the FSRCA bill's
reporting requirements are fulfilled by the ASRM, SART, and the CDC).
213. See generally BARUCH ET AL., supra note 17, at 9; Malinowski, Choosing, supra note 20, at
125; Noah, supra note 20, at 606; Parens & Knowles, supra note 20, at S1-25. But see David
Adamson, Regulation of Assisted Reproductive Technologies in the United States, 78 FERTILITY &
STERILITY 932, 938 (2002) (stating that professional societies and individuals involved with ART
have worked with one another and federal and state governments to develop an improved process
that should insure higher quality care, protect the public interest, and create public confidence in
ART services); Simpson, Rebar & Carson, supra note 203, at 1653 (arguing that self-regulation is
the most appropriate policy in the United States).
214. BARUCH ET AL., supra note 17, at 9-10.
215. Id.
216. Malinowski, Choosing, supra note 20, at 187.
217. Ethics Comm. of the Am. Soc'y of Reprod. Med., Sex Selection and Preimplantation
Genetic Diagnosis, 72 FERTILITY & STERILITY 595, 598 (1999).
218. BARUCH, KAUFMAN & HUDSON., supra note 28, at 5. The figure of 39% (the percentage of
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demand increases for certain PGS tests, the professional societies will not be able
to enforce restrictions on genetic tests.
While ASRM and other professional societies are skilled at producing
guidelines for proper medical care and procedures, such societies may not be best
suited to address the broader social and moral implications of PGS. They have
not conducted national surveys of public opinion nor engaged the public in
discourse regarding PGS's potential to shape society.
A conflict of interest also hampers the credibility of professional
associations in relation to PGS. Their members benefit most from practice
guidelines that limit PGS just enough to prevent government regulation, but
otherwise permit widespread practice. Clinicians who perform ART, PGS, and
other reproductive genetic tests comprise the leadership of the professional
societies and set their policies. While these individuals should have a seat at the
table to discuss potential PGS regulations, they represent only a few of many
stakeholders. Recent advances in PGS testing dramatically elevate the
importance of public participation in developing a policy approach.
B. State and Federal Governments
Prior to examining any state or federal regulatory proposals, it is important
to examine the constitutional limitations placed on government action. The
Constitution constrains state and federal governments' abilities to interfere in the
reproductive decisions of individuals. In designing a regulatory approach that
touches reproductive decision-making, the government should not infringe the
constitutionally protected privacy rights of American citizens. During the last
seventy-five years, the Supreme Court has established a Fourteenth Amendment
due process right granting persons the privacy to make reproductive decisions
free from undue governmental interference.2t 9 In order to survive a Fourteenth
Amendment Challenge, the government intervention must be closely tailored to a
clinics that are willing to provide non-medical sex selection in the absence of another reason for
undergoing PGS) was calculated from the data in the article, which stated that 42% of 137 clinics
offered PGS for non-medical sex selection and only 7% of those would only provide the procedure
if there was another reason to undergo PGS.
219. Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833 (1992) (reaffirming the major
holding of Roe, but permitting the government to make laws to protect the life of the mother and to
demonstrate respect for the embryo after viability); Roe v. Wade, 410 U.S. 113 (1973) (granting
women the right to decide whether to have an abortion within the first two trimesters of pregnancy
without governmental intervention); Eisenstadt v. Baird, 405 U.S. 438 (1972) (extending the
constitutional right granted in Griswold to unmarried persons); Griswold v. Connecticut, 381 U.S.
479 (1965) (granting constitutional privacy protection to a married couple's decision to use
contraception); Skinner v. Oklahoma, 316 U.S. 535 (1942) (protecting an individual's right to
reproduce from unwanted government sterilization).
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legitimate and significant state interest that outweighs the parental privacy
interest. 220 Fourteenth Amendment protection extends to decisions regarding
"marriage, procreation, contraception, family relationships, child rearing, and
education" as they involve "the most intimate and personal choices a person may
make in a lifetime. 221
Without question, PGS involves some of the most intimate and private issues
of human life.222 In certain instances, the decision to use PGS is highly analogous
to other constitutionally protected reproductive rights.223 In Skinner v. Oklahoma,
the Supreme Court recognized the right to reproduce as one of the most
fundamental civil rights. 224 For some infertile individuals, PGS provides the best
opportunity to have a child.225 In the absence of a compelling state interest, the
state should not deny infertile couples the ability to obtain fertility treatment.226
Other uses of PGS are directly linked to the decision of whether to
reproduce. John Robertson has eloquently argued that a decision should fall
under the sphere of protected procreative liberties if it is "centrally connected
with reproductive choice" and if its use is unlikely to cause harm to others.227
From this basis, Robertson argued that if the information provided by PGS might
"strongly and plausibly impact a couple's willingness to reproduce," PGS is
sufficiently related to the decision to procreate that it should be protected.228
While this principle provides a plausible standard, Robertson applies it too
broadly. He argues that the importance of a genetic selection should rest "within
a broad spectrum with the couple., 229 For decisions that could be rationally
related to reproductive goals, Robertson argues that the decision to use PGS
220. Casey, 505 U.S. at 838; Zablocki v. Redhail, 434 U.S. 374 (1978) (holding that when a
"statutory classification significantly interferes with the exercise of a fundamental right it cannot be
upheld unless it is supported by sufficiently important state interests and is closely tailored to
effectuate those interests" (emphasis added)); see also Note, Assessing the Viability of a
Substantive Due Process Right to In Vitro Fertilization, 118 HARV. L. REv. 2792, 2805-08 (2005).
221. Casey, 505 U.S. at 851.
222. PRESIDENT'S COUNCIL, supra note 112, at 10.
223. Robertson, supra note 105, at 20-21.
224. Skinner, 316 U.S. at 536.
225. See, e.g., Munn& et al., supra note 37, at 331 (finding that in a sample of 301 patients with
a history of recurrent miscarriage, patients had lost 87% of their pregnancies before PGD compared
to losing only 16.7% after using PGD); Verlinsky et al., supra note 34, at 219.
226. Robertson, supra note 105, at 20-21. Infertility does not create a positive right to ART,
such that the government must secure and pay for treatment, only a negative right that the
government must not prevent couples from attempting to have a child.
227. Robertson, supra note 197, at 455.
228. Id. at 456-57, 460-68.
229. Id. at 465.
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should demonstrate sufficient importance to the couple to warrant protection.23°
Such an interpretation would provide constitutional protection for parents to use
PGS to screen for nearly any genetic condition.231
The Supreme Court's recent decision in Gonzales v. Carhart places
Robertson's analysis of the breadth of parental autonomy into question.232 The
Court held that "[w]here it has a rational basis to act, and it does not impose an
undue burden, the State may use its regulatory power to bar certain procedures
and substitute others, all in furtherance of its legitimate interests in regulating the
medical profession in order to promote respect for life, including life of the
unborn. 233
As noted above, the language in Carhart and Casey may open the door for
the government to extend its interest in the unborn to all embryos, even those
outside the uterus.234 In that case the government could enact policies to
demonstrate respect for preimplantation embryos created through IVF and PGS.
Under current IVF practice, parents are at liberty to discard morphologically
unsound embryos or embryos they do not intend to use. Constitutional protection
for reproductive liberties should extend to the decision to discard unsound or
unused embryos. To avoid the destruction of unwanted embryos, the government
may seek to reduce the number of excess embryos created, but it should not be
able to require a couple to undergo additional cycles of IVF just to avoid
discarding embryos.
The question is whether the decision to discard embryos because one
chooses not to reproduce differs fundamentally from the decision to discard
embryos for specific genetic reasons through PGS. While both decisions entail
discarding an embryo, the first decision necessarily involves a reproductive
choice, while the other does not. Selecting one embryo over another because of a
230. Id. Robertson continues this analysis to argue in favor of protected selection for genes
associated with gender, perfect pitch, and sexual orientation. He argues that only selection for eye
color and hair color might be trivial enough to fall outside constitutional procreative liberty
protections. Id.
231. Id. at 461-68.
232. Gonzales v. Carhart, 127 S. Ct. 1610 (2007), upheld the Partial-Birth Abortion Ban Act of
2003, after finding that Nebraska's partial birth abortion statute violated the Constitution in
Stenberg v. Carhart, 530 U.S. 914 (2000). The Court also held that the government may prohibit
previability abortion procedures on the basis that "a fetus is a living organism while within the
womb, whether or not it is viable outside the womb." Carhart, 127 S. Ct. at 1627.
233. Carhart, 127 U.S. at 1633.
234. See infra Subsection III.B.2; see also Carhart, 127 S. Ct. at 1611 (stating that the
government's interest in unborn human life exists previability and postviability); Planned
Parenthood of Se. Pa. v. Casey, 505 U.S. 833, 846 (1992) (concluding that "[t]he State has
legitimate interests from the outset of the pregnancy in protecting ... the life of the fetus that may
become a child").
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preferential trait, such as eye color or hair color, does not constitute a
reproductive choice that should be protected with constitutional force. For uses of
PGS not deemed directly determinative of the decision to procreate, the
government may be able to regulate PGS in an effort to express its respect for
unborn human life by prohibiting embryos from being discarded for more
"trivial" reasons.
235
The recent advances in PGS further complicate this analysis because they
will enable parents to select for numerous traits that may not determine the
reproductive decision. Parents who would not have undergone PGS solely to
select embryos based on hair or eye color, sex, or a 40% probability of having
asthma, will be able to make those choices if they are initially undergoing PGS
for infertility or to screen out a severe disorder. Moreover, the ability to select
embryos based on the presence of a wide range of genetic traits and probabilities
may determine the decision to use PGS, even in the absence of infertility or a
severe disorder. Many of these choices would still reflect the overall goal of
having a healthy child, but the couple's decision to reproduce may not turn on
whether they can select for many of the genetic tests available through PGS. In
an unregulated market, individuals will use PGS to select for a wide range of
traits because they can, not because the ability to select for each individual
genetic condition shapes their decision to reproduce; thereby diminishing the
parental claim to constitutional protection. In instances where the genetic test is
not reasonably tied to the reproductive decision, the government will have more
leeway in passing regulation. The parents' interest in reproductive autonomy
must be balanced with the competing obligations of the government to protect
individuals and society from harms associated with PGS.
1. State Government
Within the above constitutional bounds, state governments could regulate
PGS. The ability to govern the practice of medicine has generally been retained
by the individual states, rather than ceded to the federal government. 36 State
governments currently run medical licensing boards, state health departments,
and the general practice of medicine within each state.
Despite the states' experience, few scholars have endorsed state regulation
of ART practices.237 In seeming agreement, few individual states have sought to
235. Full explication of this issue is largely beyond the intended scope of this paper, but poses
an important question for future research.
236. Edward P. Richards, The Police Power and the Regulation of Medical Practice: A
Historical Review and Guide for Medical Licensing Board Regulation of Physicians in ERISA-
Qualified Managed Care Organizations, 8 ANNALS HEALTH L. 201, 201-02 (1999).
237. See generally Malinowski, A Law-Policy Proposal, supra note 20, at 565-66; Noah, supra
note 20, at 603; Parens & Knowles, supra note 20, at S18-21. But see Rosato, supra note 20, at 80-
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regulate the practice of ART.23 s To encourage states to do so, Congress passed
FCSRCA, which required the CDC to develop a model certification program for
embryo laboratories for the states to adopt voluntarily. 239 The program requires
states to inspect and certify embryo laboratories. 240 To do so, the states must
ensure that embryo laboratories meet and maintain the standards for consistent
performance, quality assurance, record maintenance, and personnel qualifications
established by the CDC.24' To date, no state has enacted the model certification
program, preferring to leave certification regulation to the federal government
and professionals through FCSRCA and SART.242
State regulation faces collective action challenges. Passing legislation in all
fifty states will take significant time. In contrast, if researchers uncover new
individual or social harms associated with PGS, altering one federal
administrative rule would be more expedient and feasible than action by fifty
legislative bodies. In addition, permitting each state to regulate PGS
independently will invariably lead to some states that are more lax in oversight or
that do not address the practice at all. Under this scenario, the nation's PGS
practices will be as permissive as the least restrictive state. Individuals who do
not like the laws in their state could travel to another state with lesser restrictions
and have PGS performed there, diminishing the purpose of the original statute.
Finally, and most importantly, all fifty states are not well positioned to collect
data and monitor the broader social impact of different uses of PGS. Examining
use patterns from a national vantage point will provide much more information.
A federal agency could act to initiate public discussion, centralize expertise and
95 (2004) (proposing a "double-decker" approach to state and federal ART regulation).
238. Louisiana prohibits any person from destroying a fertilized human ovum, unless that ovum
fails to develop after thirty six hours. LA. REV. STAT. ANN. § 9:129 (2000); see also LA. REV. STAT.
ANN. § 9:128 (2000) (requiring ART clinics to adhere to professional organization guidelines).
Sixteen states have passed laws regarding the disposition of embryos, eggs and sperm. See
generally Nat'l Conference of State Legislatures, State Laws on Frozen Embryos: Gamete
(Egg/Sperm) and Embryo Disposition, http://www.ncsl.orgprograms/health/embryodisposition.htm
(last visited Mar. 30, 2008). Other states have passed laws relating to embryo research, which could
limit PGD or PGS to the extent that it is perceived as research on the embryo. See 720 ILL. COMP.
STAT. 510/12.1 (1993) (prohibiting research on embryos aborted for therapeutic purposes, scientific
research, or laboratory experimentation); LA. REV. STAT. ANN. § 9:122 (2007) (prohibiting research
on IVF embryos); ME. REV. STAT. ANN. tit. 22, § 1593 (2003) (prohibiting research on any live
product of conception, intra or extra-uterine); R.I. GEN. LAWS § 11-54-1 (2002) (prohibiting any
kind of experimentation on embryos before or after implantation).
239. 42 U.S.C. § 263a (2000).
240. Id. §§ 263a(d)(I), 263a(g).
241. Id. § 263a(d)(l).
242. Malinowski, A Law-Policy Proposal, supra note 20, at 551-52. In the absence of a state
program, the responsibility remains with the CDC and SART.
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data collection, analyze that data for individual and social harm, and swiftly
regulate harmful practices.
2. Federal Government
Regulation by the federal government could result from congressional
legislation or administrative agency regulation. Regardless of the approach
chosen, new legislation will be needed to regulate ART, either to expand the
roles of existing agencies or to establish the authority of a new agency. In order
to do any of the above, Congress must demonstrate that the regulation of ART
and PGS falls under the authority granted to it by the Commerce Clause of the
Constitution.243
Congress has the authority to regulate three aspects of interstate commerce:
1) the channels of interstate commerce; 2) the instrumentalities of interstate
commerce and persons or things in interstate commerce; and 3) the activities that
substantially affect interstate commerce.244 Congress previously found that
reproductive clinics engage in interstate commerce when it passed the Freedom
to Access Clinic Entrances Act of 1994.245 Subsequently, all eight circuit courts
of appeals that visited this issue upheld Congress's finding as "rational. 246 ART
clinics draw staff and patients from other states and other countries.247 They
purchase highly specialized medical supplies and equipment in interstate
commerce. 248 DNA samples must often be sent across state lines to one of a
handful of genetic testing laboratories willing to perform PGS tests.249 These
actions constitute participation in interstate commerce. In addition, in Carhart,
which challenged the constitutionality of a federal ban on partial birth abortion,
Congress's ability to regulate the practice of reproductive clinics under the
243. U.S. CONST. art. I, § 8, cl. 3.
244. Gonzalez v. Raich, 545 U.S. 1, 16-17 (2005) (citing Perez v. United States, 402 U.S. 146,
150 (1971) and NLRB v. Jones & Laughlin Steel Corp., 301 U.S. 1, 37 (1937)).
245. Freedom to Access Clinic Entrances Act of 1994, Pub. L. No. 103-259, 108 Stat. 694
(codified at 18 U.S.C. § 248 (2000)).
246. United States v. Gregg, 226 F.3d 253 (3d Cir. 2000); United States v. Weslin, 156 F.3d 292
(2d Cir. 1998); United States v. Bird, 124 F.3d 667 (5th Cir. 1997); Terry vs. Reno, 101 F.3d 1412
(D.C. Cir. 1996); United States v. Dinwiddie, 76 F.3d 913 (8th Cir. 1996); Am. Life League v.
Reno, 47 F.3d 642 (4th Cir. 1995); United States v. Wilson, 73 F.3d 675 (7th Cir. 1995); Cheffer v.
Reno, 55 F.3d 1517 (11 th Cir. 1995).
247. See Wilson, 73 F.3d at 680-81 (holding that there is substantial interstate travel involved in
reproductive health care).
248. See Id. at 680; see also Wickard v. Filburn, 317 U.S. 111, 127-28 (1942); United States v.
Soderna, 82 F.3d 1370, 1373 (7th Cir. 1996).
249. See Wilson, 73 F.3d at 680.
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Commerce Clause was not before the Court.25 ° Carefully crafted legislation
aimed at licensing, monitoring, and regulating the practice of ART and PGS in
the United States should come within the federal government's authority granted
by the Commerce Clause.
The federal government has two possible regulatory avenues for attempting
to balance the interests associated with ART: direct legislation and administrative
agency regulation. Legislative. action is particularly ill-suited to address the
concerns of a controversial and rapidly developing industry like ART.
"Legislative decision-making costs are likely to be higher when conflict of
interest makes it difficult to reach a collective decision and when uncertainty
makes it difficult to chart a desirable course of action .... ,,251 Reaching a
legislative majority on issues surrounding appropriate use of human embryos,
parental reproductive autonomy, and the perception of disability will likely prove
extremely time-consuming, if not impossible.25 2 In the meantime, the risks of
unregulated ART and PGS use will go unchecked. At the rate that ART and
genetics technology are developing, if legislation is passed, it will most likely be
outdated by the time it is enacted. The uncertainty of risks surrounding present
and future PGS practice also makes governance by legislative action especially
difficult. Rather than attempting to define for all future circumstances how the
law will apply or face the daunting task of amending the legislation with each
new development in ART, Congress should delegate the authority to regulate
ART to a specific agency and let the agency resolve the issues as they arise over
time. 53
Legislation aimed at expanding the mandate of an existing administrative
agency or creating a new administrative agency could pass more easily by
delegating controversial decisions to the expertise of the regulatory body.2 54
Agency decisions could reflect the most up-to-date scientific and sociological
research on the use of PGS. A regulatory body would also have the ability to
operate faster and with more freedom than legislative action. This more nimble
administrative approach implemented by the federal government could take two
possible forms: 1) a decentralized model with responsibilities shared among
existing federal agencies, or 2) the creation of a single federal entity to license
and monitor the use of ART in the United States.
250. Gonzales v. Carhart, 127 S. Ct. 1610 (2007); id. at 1640 (Thomas, J., concurring) (noting
that the parties did not challenge Congress's Commerce Clause authority in this case).
251. MURRAY J. HORN, THE POLITICAL ECONOMY OF PUBLIC ADMINISTRATION 14 (1995).
252. In all areas related to embryos and reproductive rights, achieving any policy that can be
agreed upon by a majority is highly difficult in the United States. See FUKUYAMA & FURGER, supra
note 20, at app. D (listing legislative activity in this field from 2001 to 2004).
253. See HORN, supra note 251, at 15-17.
254. See generally id.
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a) Existing Federal Agencies
Three existing federal agencies possess authority to regulate a portion of
PGS practice: the CDC, the Centers for Medicare and Medicaid Services (CMS),
and the FDA. However, no agency has the jurisdiction to govern the practice of
PGS as a whole, including the individual and social risks associated with the
procedure.255 Current oversight is limited to monitoring ART program success
rates, requiring general clinic sanitation and safety standards, and setting basic
laboratory requirements. None of these requirements specifically address the
unique aspects of IVF and PGS, including the challenges of genetic testing on a
single cell's DNA, the safety and efficacy of the procedures for mothers and
offspring, the ethical implications of providing PGS to screen out certain
conditions, or the social implications of increased PGS use. In order to provide
comprehensive oversight within existing federal agencies, Congress will either
need to expand the mandate of a single agency, or expand the authority of several
agencies and significantly improve their coordination.256
i) The Centers for Disease Control and Prevention
The CDC administers FCSRCA, the most specific regulation relating to
ART in the United States. 257 The Act requires that each ART program annually
report to the CDC the "pregnancy success rates[,]... the identity of each embryo
laboratory... used by such program[,] and whether the laboratory is certified...
or has applied for such certification., 258 FCSRCA requires the CDC to publish
this information annually, along with a list of the programs that refuse to
255. See 21 U.S.C. § 393(b)(2) (2000) (stating that the mission of the FDA is to protect the
public health by ensuring that "(A) foods are safe, wholesome, sanitary, and properly labeled; (B)
human and veterinary drugs are safe and effective; (C) there is reasonable assurance of the safety
and effectiveness of devices intended for human use; (D) cosmetics are safe and properly labeled;
and (E) public health and safety are protected from electronic product radiation"); 42 U.S.C. §
263a(b) (2000) (granting CMS the authority to require all laboratories that "solicit or accept
materials derived from the human body for laboratory examination or other procedure" to receive
certification); id. § 263a-2 (granting CDC the authority to promulgate procedures to approve
accreditation organizations and States to inspect and certify embryo laboratories); Ctrs. for Disease
Control & Prevention, Vision, Mission, Core Values and Pledge,
http://www.cdc.gov/about/organization/mission.htm (last visited Mar. 31, 2008) (stating that the
mission of the CDC is "[t]o promote health and quality of life by preventing and controlling
disease, injury and disability"). None of these laws permit the agency to intervene into treatment
decisions or consider the harms associated with a particular procedure.
256. Malinowski, A Law-Policy Proposal, supra note 20, at 566-68.
257. Fertility Clinic Success Rate and Certification Act of 1992, Pub. L. No. 102-493, 106 Stat.
3146 (codified at 42 U.S.C. § 263a-1 to 263a-7 (2000)).
258. 42 U.S.C. § 263a-l(a) (2000).
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report.259 The CDC has turned over all responsibility for collecting and analyzing
this information to SART.26 ° FCSRCA does not require any information on
whether PGS was performed, what genetic tests were included, or whether a
couple met diagnostic criteria for receiving such services.
Overall, the CDC has very limited power over ART clinics. FCSRCA
specifically states that the "Secretary [of the Department of Health and Human
Services] may not establish any regulation, standard or requirement which has
the effect of exercising supervision or control over the practice of medicine in
ART programs.",26' The CDC does not have the power to sanction any program
262that does not report information. SART, which performs inspections on behalf
of the CDC, has conducted on-site inspections on less than 10% of clinics to
26ensure the accuracy of reporting. 63 In addition, neither the CDC nor SART
examines whether the clinics provide care to clinically indicated patients or abide
by practice guidelines. Without the authority to regulate the practice of ART
directly or the ability to mandate that all embryo laboratories receive
certification, the CDC under FCSRCA has less power than a professional society.
ii) The Center for Medicaid and Medicare Services
While having no authority to regulate ART procedures, CMS can regulate
the quality of genetic tests performed for PGS. Congress granted this authority to
CMS through the Clinical Laboratory Improvement Act (CLIA), which regulates
diagnostic tests performed in clinical laboratories.264 By establishing standards
for laboratory testing, Congress acknowledged the importance of accurate testing
to maintaining the integrity of health care. For specific areas of testing expertise,
like microbiology and diagnostic immunology, CLIA grants CMS the authority
to create a specialty certification. Any laboratory that performs tests in an area of
specialty must become certified in that specialty by receiving a minimum score
on proficiency tests and meeting specific requirements for quality assurance,
quality control, and personnel.265 CMS has not created a specialty certification
governing genetic testing laboratories. 266 As a result, the laboratories that perform
259. Id. § 263a-5.
260. Adamson, supra note 213, at 933.
261. 42 U.S.C. § 263a-2(i)(1) (2000).
262. Id. § 263a-4.
263. Adamson, supra note 213, at 933 (stating that 30 out of 370 clinics had received on-site
inspections as of 1997).
264. 42 U.S.C. § 263a(b) (2000) (requiring all laboratories that solicit or accept materials
derived from the human body for laboratory examination to be certified); see also H. COMM. ON
ENERGY AND COMMERCE, HR. REP. NO. 100-899, as reprinted in 1988 U.S.C.C.A.N. 3828.
265. 42 C.F.R. §§ 493.801 to .807.
266. GAIL H. JAVITT & KATHY HUDSON, GENETICS & PUB. POLICY CTR., PUBLIC HEALTH AT
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the genetic tests for PGS are not required to meet proficiency standards to ensure
the accuracy of their results, nor are they required to maintain specific quality
assurance and control standards specific to genetic tests. Numerous entities,
including patients, directors of clinical laboratories, government advisory bodies,
and non-profit organizations focused on genetics, have called for the creation of a
specialty for genetic tests and heavily criticized CMS's lack of action.267
A specialty certification to ensure the accuracy of genetic tests is especially
important for PGS. Laboratories that conduct PGS testing have extremely limited
amounts of sample DNA and time to examine it. Testing protocols must be
performed with speed and precision, and errors in procedure or testing reliability
have dire consequences. Requiring minimum scores on proficiency tests and
quality assurance measures in genetic testing laboratories will greatly improve
the reliability of PGS.
iii) The Food and Drug Administration
The FDA's authority over PGS is limited because the FDA does not regulate
medical procedures or drugs used in an off-label manner. The FDA does,
however, have the authority to regulate any genetic test used in PGS that would
qualify as a medical device.268 Section 201(h) of the Food, Drug and Cosmetic
Act defines a device as "an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related article, including
any component, part, or accessory, which is ... (2) intended for use in the
diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals.,,269 The FDA therefore has the
RISK: FAILURES IN OVERSIGHT OF GENETIC TESTING LABORATORIES 4 (2006), available at
http://www.dnapolicy.org/images/reportpdfs/PublicHealthAtRiskFinalWithCover.pdf.
267. Id. at 18 (reporting that in a poll 73% of clinical laboratory directors agreed that the
creation of a genetic specialty should be created); INST. OF MED., ASSESSING GENETIC RISKS:
IMPLICATIONS FOR HEALTH AND SOCIAL POLICY (Lori B. Andrews et al. eds., 1994), available at
http://www.nap.edu/catalog.php?recordid=2057; NAT'L INSTS. OF HEALTH, ENHANCING THE
OVERSIGHT OF GENETIC TESTS: RECOMMENDATIONS OF THE SACGT (2000), available at
http://www4.od.nih.gov/oba/sacgt/reports/oversight-report.pdf; SUBCOMM. MEETING ON GENETICS,
CLINICAL LABORATORY IMPROVEMENT ADVISORY COMMITTEE, SUMMARY REPORT, September 10,
1997, available at http://wwwn.cdc.gov/cliac/pdf/gsc997.pdf; TASK FORCE ON GENETIC TESTING,
NAT'L INSTS. OF HEALTH, PROMOTING SAFE AND EFFECTIVE GENETIC TESTING IN THE UNITED
STATES: FINAL REPORT OF THE TASK FORCE ON GENETIC TESTING (Neil Holtzman & Michael
Watson eds., 1997), available at http://www.genome.gov/10001733.
268. 21 U.S.C. § 32 1(h) (2000).
269. Id.; see also FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY, CLINICAL
LABORATORIES, AND FDA STAFF: IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS 3 (2007),
available at http://www.fda.gov/cdrh/oivd/guidance/ 161 0.pdf.
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ability to regulate the commercial use of any genetic test used to diagnose a
preimplantation embryo with a specific genetic disease or chromosomal
abnormality based on its safety and efficacy.2 70 The direct safety of genetic tests
is not in question, as they are performed on cells that have already been removed
from the embryo and that will be discarded.2 71 However, the efficacy of the
genetic tests used for PGS is indirectly linked to the safety of the test, as an
inaccurate genetic test may cause parents to discard a healthy embryo or transfer
an affected one. If the FDA were to regulate, the efficacy of genetic tests could
be demonstrated in two ways: 1) the test must correctly and reliably identify the
desired gene; and 2) the presence of that gene should reliably predict the
development of the disorder.
However, the FDA has not exercised its authority to regulate the efficacy of
the majority of genetic tests offered in practice.272 This "hands off' approach
relies heavily on voluntary laboratory compliance with current Good
Manufacturing Practices, medical device reporting requirements, labeling
requirements, and on CMS regulation of genetic tests through the CLIA.273 Since
laboratories often create their own genetic tests rather than purchasing
commercial genetic testing kits, the FDA's reliance on CMS initially was
appropriate. However, there is a need for more substantial regulation of the
genetic tests used for PGS now that genetic tests are entering commercial
markets in increasing numbers, microarrays can be sold to test for a panel of
genetic conditions, and such tests are often accompanied by complex statistical
algorithms to diagnose multiple genetic conditions.274
270. interestingly, under this definition, the FDA may not have the ability to regulate the use of
genetic tests to diagnose non-health related conditions. While any genetic test could be said to
diagnose some form of "condition," the context of the statute seems to suggest that the device must
be used for disease or health related purposes.
271. Whether the removal of a cell from the blastocyst for genetic testing is harmful to the
embryo or future offspring is a different issue than the safety of the test.
272. BARUCH, KAUFMAN & HUDSON, supra note 28, at 7. The FDA does regulate certain
components used in in-house laboratory tests, known as analyte specific reagents (ASRs), so that
healthcare providers would know how the tests were being validated. See FOOD & DRUG ADMIN.,
supra note 269, at. 4 (citing 21 C.F.R. §§ 809.10(e), 809.30, 864.4020 (2007)).
273. See Sales Restriction to CLIA Regulated Laboratories that Perform High Complexity
Testing, 62 Fed. Reg. 62,252 (Nov. 21, 1997) (codified at 21 C.F.R. pts. 809, 864); FOOD & DRUG
ADMIN., DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF, COMMERCIALLY DISTRIBUTED ANALYTE
SPECIFIC REAGENTS (ASRS): FREQUENTLY ASKED QUESTIONS 5 (2007), available at
http://www.fda.gov/cdrh/oivd/guidance/l590.pdf.
274. Press Release, Genetics & Pub. Policy Ctr., Center Sees "New Era in Oversight" in Two
New FDA Draft Guidances, Sept. 7, 2006, http://www.dnapolicy.org/news.release.php?action=
detail&pressrelease id=56.
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b) New Regulatory Body
While the CDC, FDA, and CMS all have some regulatory authority over
ART that could be expanded to include PGS, the range of oversight required
exceeds each of their mandates.275 The President's Council on Bioethics stated
that "the choice between delegating power to a new federal agency or to an
existing agency or agencies should come down to the question of whether this
arena of technology and activity raises (or is likely to raise) fundamentally new
and different sorts of questions and challenges from those that have been dealt
with by existing federal agencies in the past. 276 Many of the issues associated
with assisted reproduction and genetic testing raise new challenges that do not
fall under the expertise of existing governmental bodies.277 For instance, should
parents have the right to engage in non-medical sex selection? Should they be
able to screen for genes associated with behavioral conditions such as shyness?
What are the limits of parental discretion? What are the social implications of
screening for multiple conditions? The CDC, CMS, and FDA were not designed
to assess the intricate social and ethical implications of ART and genetic
screening practices. 278 Rather than straining existing agencies to expand their
resources and expertise, as Michael Malinowski suggests, the government should
design a new regulatory body specifically to address the scientific, legal, ethical
and social challenges associated with the ever-changing world of ART. 79
An administrative agency created to oversee the practice of ART, if designed
correctly, could be centralized, flexible, and backed with legal force. Each of
these factors will be important to the ability to respond adequately to the
challenges of PGS and other developments in ART. Since the risks associated
with PGS also include the risks associated with many of the other activities of
ART practice, including IVF, ICSI, extraction and handling of gametes, and
embryo creation and storage, creating an agency to regulate PGS would also
provide the infrastructure necessary to oversee the entire practice of ART within
one federal body. When multiple agencies have jurisdiction over an area of
practice, the oversight can be disjointed. Given the uncertainty of risk associated
with PGS use, the centralization of information, expertise, and regulatory
authority would produce more complete oversight and improve efficiency in
communication and coordination.
Centralizing information and decision-making power would also give a
single regulatory body more flexibility. The flexibility to respond quickly to new
275. See PRESIDENT'S COUNCIL, supra note 112, at 76-78.
276. Id. at 189.
277. Id. at 187.
278. See id.
279. Malinowski, A Law-Policy Proposal, supra note 20, at 566.
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information would enable the policy response to evolve alongside the
technology. A centralized agency could quickly enjoin harmful practices or issue
regulatory guidance without needing to coordinate with other federal entities.
To maintain policy continuity in an area staunchly divided by religious and
political forces, the agency should be independent of the executive branch,
similar to the Securities Exchange Commission. 280 As expounded upon in greater
detail by Frances Fukuyama and Franco Furger, in today's fractured political
landscape, only an independent agency would have a chance of being supported
by special interest groups and a majority in Congress.2 81 The U.S. should not let
the politics of abortion prevent it from passing important measures to regulate the
future of other reproductive activities. Both sides have a great deal to gain from
creating some oversight for PGS practice.282 An independent agency could
evaluate the benefits and risks to both individuals and society of different uses of
PGS from a neutral position and establish regulations to curb unwarranted risks
and promote benefits.
The creation of an independent body to monitor and regulate PGS will
provide the best assurance that the risks of PGS are being considered, while the
benefits of PGS continue to remain accessible.
IV. How SHOULD THE UNITED STATES OVERSEE THE USE OF PGS?
Designing the mandate of a new regulatory entity to oversee the use of
assisted reproductive technologies, including IVF and PGS, will be challenging
because of the competing interests and ethical issues involved. Instead of trying
to resolve the differences between stakeholders, the government should pursue a
political solution that addresses areas of overlapping stakeholder interests and
balances the conflicting interests.283
The remainder of this Article argues for the creation of a new regulatory
entity to oversee the practice of ART in the United States. Section IV.A identifies
the major stakeholders and the factors the government should consider in policy
development. Section IV.B outlines the development of policy objectives for the
agency and examines possible regulatory approaches. Section IV.C proposes the
creation of the Assisted Reproductive Technology Authority and outlines its
initial responsibilities.
280. See FUKUYAMA & FURGER, supra note 20, at 293-300.
281. See id. at 293.
282. See id.
283. See Charo, supra note 190, at 20-23 (advocating a similar approach to addressing the
conflicting interests associated with embryo research).
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A. Factors To Consider
The relevant factors in developing PGS policy should reflect the interests of
all stakeholders involved in the procedure or impacted by it. ART stakeholders
include the individuals who want to use ART, offspring born via ART, members
of society affected by its use, and ART practitioners. Their interests fall into four
categories that can be used to define the mandate of a new regulatory body. The
government should strive to preserve these stakeholders' interests by developing
a regulatory approach that accomplishes the following goals: 1) protecting the
health and well-being of individuals; 2) protecting members of society from
harms caused by ART; 3) protecting individual autonomy to make reproductive
decisions; and 4) protecting the interests of the medical profession. To develop a
regulatory strategy, the government should rank these goals and establish an
infrastructure to balance the competing interests when the goals conflict.
1. Protecting Individual Health and Well-Being
The government's highest priority should be to protect the women who
undergo ART and their children, as they represent the most vulnerable entities
involved in the procedure. Couples who undertake ART procedures are often
willing to take disproportionate personal risks to improve their chances of having
a healthy child. The children born via ART are subjected to additional risks, but
they cannot consent or participate in discussions regarding the use of the
procedure.
The government can protect women by improving their access to
information and monitoring the clinics that provide ART services. While women
should always retain the autonomy to determine what risks to accept with respect
to reproductive procedures, the government can play an important role in
informing their decision. Promoting or requiring genetic counseling to explain
the risks of ART and PGS misdiagnosis to parents would assist them in making
decisions regarding embryo selection. Efforts to fund research on women's
health outcomes, ensure access to the most up-to-date health information, and
provide information on other viable treatment alternatives will improve women's
ability to make an informed reproductive decision.284 Likewise, by licensing all
ART clinics and requiring them to meet minimum quality standards, the
government can better assure women undergoing ART procedures of their safety.
The government can also take several actions to reduce the potential harm to
284. Women should be told that alternatives to IVF and PGD exist. For instance, they could
obtain a donor egg or a surrogate carrier. AM. SOC'Y REPROD. MED., THIRD PARTY REPRODUCTION:
A GUIDE FOR PATIENTS (SPERM, EGG AND EMBRYO DONATION AND SURROGACY) 3 (2006), available
at http://www.asrm.org/Patients/patientbooklets/thirdparty.pdf.
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children born through ART. Increasing research funding to monitor the health
and well-being of children born through the procedures would greatly improve
our understanding of the extent and magnitude of the health risks. This research
would also shed light on practices within clinics, such as multiple embryo
transfers, that negatively impact the overall health of ART children.
In addition to funding research, the government could seek to develop
practice guidelines for assessing the risk/benefit ratio of engaging in PGS for a
certain condition. Physicians should examine the benefits and the risks in a
systematic manner. Numerous factors contribute to the benefit provided by the
genetic selection, including 1) gene penetrance; 2) availability of treatment for
the condition; 3) tolerability of the treatment; 4) efficacy of treatment; 5) impact
of the disorder or characteristic on the individual; 6) the known genetic
contribution to the development of the disorder; and 7) age of onset. These
factors should be weighed against the known risks to children associated with
IVF and PGS. Practice guidelines, while not mandated, can provide significant
assistance to physicians attempting to determine which genetic selections provide
sufficient benefit to outweigh the risks of PGS. Couples could also use the
guidelines to make their own decisions about what types of genetic tests they
should pursue.
2. Protecting Society
The government has an interest in protecting society from the potential
negative effects of PGS. The collective use of PGS may result in increased health
disparities and discrimination against individuals with the diseases and
characteristics commonly selected against. The government also maintains an
interest in demonstrating respect for potential human life.285
PGS impacts society less directly than the individuals engaged in the
procedure; therefore, the government's interests in protecting society are less
immediately relevant. However, if data begin to substantiate that PGS use will
significantly increase health disparities or discrimination against disadvantaged
groups, these risks should be given significant weight that in some instances
could outweigh individual autonomy to use PGS. The government's interest in
demonstrating respect for unborn human life should also be weighed against
individual interests in using PGS in light of significant public discussion and
consultation on the issue.
In order to protect society, the government should seek a regulatory strategy
that enables it to identify social risks as they arise both in attitude and in practice.
This will entail promoting extensive public discourse and monitoring
discriminatory practices. These goals could be accomplished through notice and
285. See Gonzales v. Carhart, 127 S. Ct. 1610 (2007).
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comment proceedings and public hearings, monitoring the use of PGS for certain
conditions, predicting future demand, and employing a diverse staff of experts to
identify and raise pertinent issues. Each of these features will be especially
important as the government determines whether and under what conditions
parents can screen for moderate medical and non-medical conditions.
3. Protecting Reproductive Autonomy
Any government policy regulating ART should start from the foundation of
protecting the ability of American citizens to make choices about whether to have
a child through assisted reproduction and whether to implant an embryo with
certain genetic characteristics. However, as noted above, constitutional protection
for reproductive autonomy is not boundless.2 86 Reproductive autonomy should be
granted less priority than individual and social harm because in some instances,
those interests will trump an individual's right to make reproductive decisions.
The government can intervene in the practice of ART and PGS without
infringing on the Constitution in two instances. First, if the intervention restricts a
fundamental right, it must be supported by "sufficiently important state interests
and . . . closely tailored to effectuate only those interests., 287 Second, in cases
where the intervention does not restrain a fundamental right, the government may
regulate so long as a rational basis exists for the regulation.288 If the
governmental interest is important enough to outweigh an individual's privacy
rights, presumably the government should act. In the absence of a fundamental
right and a substantial state interest, the government should critically examine
whether intervention provides the best course of action.
Decisions regarding reproduction and child-rearing remain extremely
personal, even if not constitutionally protected. Parents bear responsibility for
raising their children and may have a wide range of reasons for wanting to select
for specific traits. In these instances, Mill's principle again becomes salient
289 
-
the government should restrain itself from intervening in the decisions of citizens
regarding PGS unless those decisions cause direct harm or pose a substantiated
threat to others. The agency should develop a framework to balance parental
interests against the individual and societal risks associated with some uses of
286. See supra Section III.B.
287. Zablocki v. Redhail, 434 U.S. 374, 388 (1978); see also Planned Parenthood of Se. Pa. v.
Casey, 550 U.S. 832, 878 (1992) (striking a balance between the state and individual interests in
reproductive decision-making as opposed to applying strict scrutiny analysis); Carhart, 127 S. Ct.
at 1627 (affirming the balancing approach taken in Casey). No court has addressed whether
individuals possess a constitutionally protected, fundamental right to make decisions regarding
embryo selection via PGS.
288. Cleburne v. Cleburne Living Ctr., Inc., 473 U.S. 432, 440 (1985).
289. MILL, supra note 81, at 73-74.
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PGS. This framework should reflect the relative priority of interests and the
amount of evidence supporting each interest. Maintaining this level of regulatory
restraint provides credibility to the regulations that the government does institute,
especially if the regulations are established in a transparent way.
4. Practitioners' Interests
In developing a regulatory strategy for PGS, the government should also
consider and protect the interests of practitioners, but they should receive the
lowest priority of the four stakeholder groups. Practitioners have a strong interest
in enabling their patients to have healthy children and in protecting the integrity
of the physician-patient relationship. Government efforts to improve access to
information and ensure the quality of laboratory procedures would help promote
these interests. However, practitioners are likely to view substantive regulations
aimed at restricting the professional decision-making as unjust interference in the
physician-patient relationship.
Practitioners are also wary of well-meaning but poorly crafted legislation
that will restrict the use of PGS or result in additional burdens for the ART
patient population.29° For instance, ART practitioners heavily criticize
FCSRCA's ART registry for its unintended consequences. First, they view the
registry as an unfunded mandate that pushes reporting costs on to patients or
291Iproviders. Second, by publishing the success rates of clinics that do report,
they argue that FCSRCA might encourage clinics with low success rates to avoid
reporting or to begin selectively accepting those patients most likely to become
292pregnant. Patients with poorer prognoses may have difficulty accessing care.
Both increases in cost and provider unwillingness to treat certain patients could
further limit the population that can access ART treatment.
Many practitioners believe that legislative or governmental regulation in
general will have a "chilling effect" on PGS practice as a whole in the United
States.293 Since insurance carriers often do not cover PGS, couples are not
financially bound to physicians or facilities. Many couples will travel to different
countries in order to obtain access to the reproductive treatments they desire.294
290. Simpson, Rebar & Carson, supra note 203, at 1656-59.
291. Id. at 1658. While it may seem fair that those who provide and use ART pay for reporting,
the providers argue that these extra costs prevent others from accessing ART.
292. Id. Simpson and colleagues provide a number of examples of how clinics might select
healthier patients.
293. Id.
294. Guido Pennings, Legal Harmonization and Reproductive Tourism in Europe, 19 HUM.
REPROD. 2689, 2690-91 (2004); Press Release, European Soc'y of Human Reprod. & Embryology,
Europe Struggles To Meet the Legal, Ethical and Regulatory Challenges Posed by More Patients
Traveling Abroad for PGD, July 2, 2007, http://www.eshre.com/emc.asp?pageld=936.
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As a result, countries with more relaxed regulations on PGS will capture more of
the market, not only for patients and consumers, 295 but also for the development
of new genetic tests for predictive genomics.2 %
Not all practitioners are opposed to governmental oversight. Although some
members of SART have argued that self-regulation is the "most appropriate
policy in the United States, '297 others support the development of an independent
oversight authority derived from a partnership between patients, providers, and
the public. 298 Those members supporting an independent authority advocate
regulatory initiatives that include the following: "mandatory compliance,
meaningful sanctions, uniformity in reporting, on-site inspection and validation,
and development of practice standards, research standards, education standards,
and counseling standards, as well as access to insurance coverage and research
funding, and a limitation of regulation. 299 The backing and continued
participation of ART practitioners is invaluable to any oversight proposal. Their
desire for more stringent enforcement mechanisms and uniform practice
standards should form the foundation of any regulatory policy.
Balancing these conflicting interests and concerns in one political initiative
will be extremely challenging. However, it is imperative to establish
infrastructure to address these questions as PGS technology develops.
B. Policy Development
PGS policy should develop in two steps. The agency should first examine
the four policy goals described above to identify areas of overlapping interest
among the potential stakeholders - what policy goals would benefit all or most of
them? Addressing those needs should be the initial mission of the regulatory
entity. Next, the agency should consider the areas where the policy goals conflict
with one another. It should develop a regulatory framework that balances the
interests in accordance with their level of priority.
1. Aligning Similar Interests
Governmental initiatives that benefit all or most stakeholders should form
the fundamental features of a new regulatory policy. Achieving the following
goals would improve the practice of ART for everyone: 1) ensuring the safety
and efficacy of all services provided; 2) improving access to information
regarding the risks and benefits of ART; and 3) providing increased analysis of
295. See, e.g., Spar, supra note 57, at 214-16.
296. See, e.g., Simpson, Rebar & Carson, supra note 203, at 1658-59.
297. See Id. at 1656.
298. See Adamson, supra note 213, at 941.
299. Id.
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the impact of ART, and especially PGS, on both individuals and society.
The agency's first objective should be to develop procedural regulations to
ensure the safety and efficacy of all procedures performed in ART clinics, as well
as the reliability of the genetic tests used in conjunction with PGS. The United
Kingdom's Human Fertilisation and Embryology Authority (HFEA) provides an
excellent licensing model that could be modified for implementation in the
United States to ensure the quality of both ART procedures and genetic tests.300
Under the U.K. licensing approach, clinics must be licensed to engage in any
activity that involves the ex vivo creation of a human embryo, the storage of
embryos and gametes, or research involving embryos.
301
By requiring each clinic that offers ART services to obtain and maintain a
license to practice, the agency could require all clinics to have appropriately
trained staff and maintain quality assurance standards. In addition, by licensing
the clinics, the agency could ensure that all clinics reported practice and outcome
information to a central database for analysis of child and maternal health risks.
The licensing approach would also grant the agency the ability to sanction clinics
that do not comply by suspension or revocation of their license.
This licensing approach can be broadened to include laboratories that
provide genetic tests for PGS. PGS procedures require a degree of expertise and
302
skill beyond that of a typical diagnostic testing laboratory, given that it
requires testing on a single biopsied cell within a short window of time.
Laboratories that provide these services should also receive licenses that
demonstrate staff qualifications, procedures to avoid misdiagnoses or embryo
mix-ups, and the reliability of their tests. In addition, the agency should create
procedural standards for gene variations that may be identified through PGS,
based on the reliability of available genetic tests, the variation's contribution to
the particular disorder (alone or in combination with other identifiable genes),
and each variation's penetrance.
The agency's second objective should be to increase understanding of PGS
practice. Any policy approach should include provisions to sponsor additional
research on ART, create an ART central database to gather and analyze
information, and disseminate information to patients, physicians, and the public
regarding the uses of PGS.
300. See also FUKUYAMA, supra note 198, at 203-04; Fahrenkrog, supra note 20, at 779; Parens
& Knowles, supra note 20, at S18-21; cf PRESIDENT'S COUNCIL, supra note 112, at 220-24.
301. Human Fertilisation and Embryology Act. 1990, c. 37, § 5 (U.K.); see also Margaret Foster
Riley with Richard A. Merrill, Regulating Reproductive Genetics: A Review ofAmerican Bioethics
Commissions and Comparison to the British Human Ferilisation and Embryology Authority, 6
COLUM. Sci. & TECH. L. REv. 1 passim (2005) (providing a detailed description of the licensing
process).
302. GENETICS & PUB. POLICY CTR., supra note 127.
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The agency should establish key research objectives and provide funding to
address the unanswered questions regarding PGS use. For instance, studies
should be done to determine whether embryo biopsy harms embryo development
or affects the long-term health of children. 30 3 The government should also
sponsor research on public sentiment regarding the appropriate uses of PGS and
the likely demand for genetic tests.
Since PGS practice will continue while this research is being performed, the
government should create a central database of information on IVF and PGS
procedures. ART clinics should be required to submit information on all IVF and
PGS procedures performed, including the following: the medical history of the
couple; the procedures used to create the embryo; the number of embryos created
and transferred; the implantation, pregnancy, and live birth success rates; the
health outcomes of all women; the immediate health outcomes of all babies born
via the procedure; all genetic tests performed; and embryo selections made. ART
clinicians should ask all parents at the time of ART treatment initiation to
consent for this information to be reported to the federal government and used for
research. In addition, parents and children born through ART procedures, upon
reaching the age of assent, should be asked to consent to having the child's health
status reported to the federal database on an annual basis for monitoring and
research. Pediatricians could simply forward check-up information to the
database stripped of all identifying information and in compliance with all
federal privacy requirements.30 4 The database could expedite identification of
risks to children and women and could ensure that physicians and patients make
reproductive decisions on the best information available.
Although additional information on the outcomes of ART and PGS
procedures will provide benefit, ART providers are likely to resist the imposition
of a mandatory reporting requirement in addition to FSCRCA. FSCRCA's
reporting requirements should form the foundation of the central database and be
broadened to include additional information related to PGS. Maintenance of
FSCRCA's reporting requirements should be transferred from the CDC to the
new regulatory body. Providing proper funding to establish the database and
assist practitioners in meeting the reporting requirements should also alleviate
some of their resistance.30 5
303. Federally sponsored research on whether embryo biopsy impedes embryo development
will most likely violate the Dickey-Wicker Amendment. See Balanced Budget Repayment Act of
1996, Pub. L. No. 104-99 § 128, 110 Stat. 26, 34. This amendment should be repealed to permit
research on the effectiveness of ART to proceed. Research on the long-term health outcomes of
children born via PGS will be less likely to violate the amendment, as the research could start from
their birth.
304. See 45 C.F.R. § 164.501 (2007).
305. See Simpson, Rebar & Carson, supra note 203, at 1658.
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The government should also create educational materials detailing the risks,
benefits and alternatives to IVF and PGS for distribution to physicians, patients
and the public. Stimulating public debate will be essential to creating effective
policy regulations for PGS use.
The third policy goal should be to improve analysis of PGS's effect on both
individuals and society. Monitoring the demand for certain genetic tests reported
in the PGS central database will be essential for understanding the potential
social risks associated with PGS use. Policymakers should combine this data with
information from public discussion and surveys to determine whether access
barriers to PGS affect health disparities or whether individuals use PGS in ways
that reinforce discrimination.
2. Balancing Conflicting Interests
The most significant challenges of regulating PGS will arise when the
interests of the various stakeholders conflict. Conflicts are most likely to occur
when prospective parents want to use PGS in ways that threaten harm to a child
or society. The government must develop a strategy for handling these conflicts.
Examining policy approaches taken by other countries provides insight for
developing U.S. policy.
Other countries have taken a range of approaches to minimize the risk of
harm from PGS. Banning the procedure altogether, as Germany, Austria,
Switzerland, and, more recently, Italy have done, is overly restrictive given the
speculative nature of social harms arising from PGS. 30 6 However, other
approaches warrant further consideration. Countries in which PGS occurs have
generally selected two regulatory features: a serious impairment requirement and
an indication analysis. The severe impairment requirement restricts the use of
PGD to testing only those genetic or chromosomal disorders that would cause
severe impairment. Under the indications analysis approach, an agency reviews
each indication on a case-by-case basis and determines which uses are
appropriate.
While both of these approaches offer improvements over the United States'
current laissez faire system of ART regulation, neither approach is well suited to
our political system or to address recent advances in PGS technology. The severe
impairment requirement, a highly precautionary approach, impinges significantly
upon reproductive liberty in the absence of substantiated risk. The indications
analysis approach requires an excessive amount of oversight and monitoring and
favors precaution over reproductive freedom. In the absence of substantiated risk
of harm, restricting the use of reproductive technologies may run afoul of
constitutionally protected reproductive liberties. Likewise, such an approach will
306. See supra notes 171-174 and accompanying text.
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likely receive significant resistance from both physicians and patients. A more
politically feasible and less-disruptive regulatory model would establish safety
and efficacy regulations, monitor the use of ART practice, and then be prepared
to intervene if and when risks appear on the horizon. This approach offers
significantly more protection than the current lack of regulation, without
unnecessarily stifling the development and use of recent advances in ART.
a. Severe Impairment Requirement
Nearly all forms of regulation regarding PGS require that the risk of the
condition or disorder tested for be sufficiently grave.3 °7 Most countries and
professional societies that allow PGS limit genetic testing of embryos to only
those conditions that will result in serious or severe impairment. For instance, the
Netherlands restricts PGS use to "serious conditions.,, 30 8 In such countries, the
only goal of PGS is to bring about the birth of a healthy child.309 Some regulatory
bodies have gone further to restrict PGS to only those conditions for which
medicine cannot provide a remedy; for example, the Australian Medical
Association recommends PGD testing only when the disease is permanent. 310 For
the most part, governments and professional societies have left the decision of
what qualifies as a "serious" or "severe" condition to the patient and the
physician.311
The definition of "severe impairment" largely determines the scope of the
307. Knoppers & Isasi, supra note 172, at 2696. Examples of countries with a severe or serious
impairment requirement include the United Kingdom, Japan, India, France, and the Netherlands. Id.
at 2697.
308. See Health Council of the Neth. Pre-implantation Genetic Diagnosis, in REPORTS 2006:
EXECUTIVE SUMMARIES 9, 9 (2006), available at http://www.gezondheidsraad.nl/pdf.php?ID
I 646&p = 1.
309. See Knoppers & Isasi, supra note 172, at 2696-97 (describing policies in the Netherlands,
France, Japan, the United Kingdom, and Australia) (citing Law No. 94-654, art. R2131-7 (1994)
(Fr.); HUM. FERTILISATION & EMBRYOLOGY AUTH., CODE OF PRACTICE (5th ed. 2001); Act
Containing Rules Relating to the Use of Gametes and Embryos [The Embryos Act], Stb. 2002, 338
(Neth.), available at http://www.minvws.nl/includes/dl/openbestand.asp?File=/images/
engembryowettekst-tcm20-107819.pdf, JAPAN SOC'Y FOR HUMAN GENETICS ET AL., GUIDELINES
FOR GENETIC TESTING (English ed. 2004), available at http://jshg.jp/pdf/lOacademies-e.pdf).
Permitted indications tends to include the screening for X-linked disorders, autosomal recessive
disorders (such as cystic fibrosis, Tay-Sachs, and spinal muscular atrophy), autosomal dominant
disorders (such as myotonic dystrophy and achondroplasia), and chromosomal abnormalities. See,
e.g., JAPAN SOC'Y FOR HUM. GENETICS ET AL., supra, at 7.
310. AUSTRALIAN MED. ASS'N, HUMAN GENETIC ISSUES 3 (2002), available at
http://www.ama.com.au/web.nsf/doc/SHED5G7DBE/$file/healths-gd-ps-human%20genetics%20i
ssues.pdf.
311. See Knoppers & Isasi, supra note 172, at 2699.
HeinOnline -- 8 Yale J. Health Pol'y L. & Ethics 347 2008
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
regulation, but identifying those disorders that cause a "severe impairment" is
extremely difficult. In fact, ART practitioners Joe Leigh Simpson and colleagues
have argued that "[c]odifying diseases for which PG[S] should or should not be
allowed is hopelessly naive . ..."312 Does severe impairment imply that a
disorder shortens the life span of the individual? Must the disorder be incurable?
What if the gene only confers a small probability of a very severe disorder?
Should the disorder qualify the individual for disability benefits, such that one or
more major life activities are limited? What if it does not present until later in
life, but has very severe symptoms, like Huntington's disease or Alzheimer's
disease?
If defined narrowly to only include those disorders that result in severe
suffering and death at an early age, PGS use will continue to have a minimal
impact. This approach would permit physicians to provide PGS only in cases
where the benefit obtained by parents in selecting against a disease or disorder
substantially outweighs any risks. As a result, fewer offspring would be born
from the procedure.
Under this narrow definition, the social impacts of PGS would be limited as
well. PGS for serious disorders would most likely be covered by insurance, such
that lack of financial access to care will not significantly exacerbate health
inequities, except between the insured and uninsured. A narrowly defined severe
impairment requirement would also limit discrimination, as only a small
population would have access to the procedure and a smaller population would
be living with the disorders.
A more broadly defined severe impairment requirement that included, for
example, disabilities such as blindness and deafness, might expand the potential
for certain social harms associated with PGS. Compared to the narrow serious
impairment approach, increased numbers of individuals would already live with
disorders identifiable by PGS. This could increase discrimination against
individuals living with the disorders and create greater disparities in use.
313
The severe impairment requirement is under-inclusive. Preventing
individuals from selecting for traits that do not confer a severe impairment is not
warranted by risks to either the offspring or society. While being born through
IVF and PGS increases the risk that a child will have a serious health
complication, the overall risk remains relatively low.3 14 While these risks should
be significant enough to outweigh the benefit of selecting for many non-medical
312. Simpson, Rebar & Carson, supra note 203, at 1658.
313. Discrimination could increase in two ways. First, by offering a way for parents to avoid
having a child with a specific disorder, PGS serves to increase discrimination against those with the
disorder, especially if only wealthier people have access. Secondly, by screening for a wider range
of conditions, more people will be exposed to discrimination.
314. See generally supra note 15.
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traits, there is not sufficient evidence of harm to offspring or society at this time
to warrant restriction of PGS use to only the most severe disorders.
The ability to select for non-severe traits in addition to a severe trait will
further undermine the logic of the severe impairment requirement. For couples
who have met the initial clinical indication requirement to undergo PGS, such
that the benefits of screening for a certain condition already outweigh the risks,
screening their embryos for additional genetic variations presents no additional
risk to the offspring or the mother. As a result, a severe impairment requirement
would prevent parents from accessing additional information, medical or non-
medical, about their embryos for non-serious conditions. In this scenario, the
only justifiable arguments against permitting the parents from screening for
additional conditions are that such screening will result in social harm.
Social concerns that may justify the severe impairment requirement
approach arise largely from the potential for discrimination and respect for the
embryo. As noted above, many countries limit PGS use to only severe conditions
to limit the extent of eugenic practices and discrimination.315 However, this
approach is overly broad as an effort to protect society from discriminatory
practices. Many alleles that are not associated with serious impairment do not
raise concerns about discrimination. For instance, parents selecting an embryo
that is a tissue match to a sick sibling, an entirely non-disease related trait, would
not constitute discrimination against individuals with other tissue types. Consider
also screening against alleles associated with a common but not severe allergy,
such as an allergy to cats. Permitting parents to select embryos on this basis
would benefit cat-loving parents, while not harming other members of society. In
this regard, the severe impairment approach appears overly rigid without being
substantiated by viable risks.
In sum, the severe impairment requirement has numerous drawbacks. By
restricting the conditions for which PGS can be used, the severe impairment
requirement unnecessarily constrains parental autonomy in light of the known
individual and social risks. The policy would require the government to define
those disorders that qualify as "severe," which would be extremely challenging.
Such a policy approach also has the potential to increase discrimination against
individuals with the listed disorders. To avoid these concerns, the government
should err on the side of granting parents expansive autonomy to make choices,
which should only be limited in cases of substantiated harms to others.
b. Indications Analysis Approach
Another possible approach would be to examine each indication, or specific
reason for conducting PGS, on a case-by-case basis to determine the risks to
315. Knoppers & Isasi, supra note 172, at 2697.
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individuals and society.316 A few legal and ethical scholars have suggested that
the United States model its ART regulations after the indications approach taken
by the United Kingdom's HFEA.3 Most notably, Lori Knowles and Erik Parens
suggest the creation of a Federal Reprogenetics Technologies Board,318 and
Frances Fukuyama and Franco Furger recommend the creation of an independent
federal agency to address human biotechnologies and ART.3 19 While the creation
of an independent federal agency to regulate the practice of ART is the best
strategy, the HFEA indications approach has significant flaws that leave it
unprepared for the future challenges of PGS.
Under the U.K. indications approach, clinics are prohibited from engaging in
any activity that involves the ex vivo creation of a human embryo, the storage of
embryos and gametes, or research involving embryos, except as permitted by an
HFEA license.320 ART clinics must receive a license approving the use of IVF
and PGS as "treatment services.,, 32 1 Licenses are narrowly tailored to specific
indications. In order to provide PGD, the HFEA Code of Practice requires clinics
to submit a new application for every new PGD indication it wishes to provide
322and for every new genetic test or combination of tests they want to use.
The indications approach has significant benefits. The HFEA is dexterous at
responding to scientific developments that affect ART research and practice.323
The regulatory infrastructure enables the authority not only to evaluate the social,
ethical, and scientific implications of a particular indication, but it also allows the
authority to react quickly and effectively to changes in information by issuing
licenses or suspending them. The indications approach also permits clinics to
evaluate couples on the full extent of their personal situation, rather than
evaluating uses only.324
By combining comprehensive monitoring and indication licensing, the
indications-based approach offers a complete examination of all of the risks to
offspring. By keeping records of each child born via PGS, the HFEA can rapidly
identify any adverse health outcomes associated with the procedure. The agency
can easily incorporate new risk information into existing practice by initiating
316. For instance, sex selection for family balancing and sex selection to avoid an X-linked
disorder would use the same test for different indications.
317. FUKUYAMA & FURGER, supra note 20, at 14-23; Fahrenkrog, supra note 20, at 779; Parens
& Knowles, supra note 20, at S18-21. The HFEA examines each indication for conducting PGS.
318. Parens & Knowles, supra note 20, at S18-21.
319. FUKUYAMA & FURGER, supra note 20, at 14-23.
320. Human Fertilisation and Embryology Act, 1990, c. 37, § 5 (U.K.).
321. Id. at § 3.
322. HUMAN FERTILISATION & EMBRYOLOGY AUTH., CODE OF PRACTICE pt. A. 13.8-9 (7th ed.
2007), available at http://cop.hfea.gov.uk/cop/pdf/COPv2.pdf
323. Riley & Merrill, supra note 301, at 58.
324. See Id. at 57-58.
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investigations, 325 considering new data during the licensing process or modifying
existing licenses. Because the HFEA examines each PGS indication, the risks
and benefits can be weighed in the most accurate manner possible. Overall, a
licensing approach permits PGS use to expand as genetic testing and
reproductive technology improves, but in a controlled manner.
Examining PGS uses on a case-by-case basis also provides a thorough
method for identifying and considering social impact. An independent regulatory
body like the HFEA would have the ability to consider the social impact of
permitting an individual indication of PGS, while monitoring the numbers of
individuals undergoing PGS for a specific purpose to determine if a broader
social effect may occur. Only by overseeing usage and keeping in touch with
public sentiment could a society adequately attempt to weigh important social
interests, minimize health disparities, eliminate discrimination, and define the
appropriate treatment of embryos.
However, as practiced by the HFEA, the indications approach also requires
more government intervention than the risks of PGS practice currently warrant.
Requiring a committee to evaluate and license each clinic for each potential use
or combination of uses is overly burdensome, expensive, and time-consuming.
As the number of genetic tests expands and PGS testing for multiple traits
becomes available, licensing each clinic to use each specific indication will be
impossible. UK clinicians have argued that licensing each use interferes with the
doctor-patient relationship and patient privacy. 326 Others complain that the
licensing system creates unnecessary delays for time-sensitive treatments and
further delays the already limited access to treatments available to underserved
populations.
327
The United States could choose a modified approach that requires agency
approval each time a new genetic test was provided for PGS. While this would
greatly reduce the time and expense required for PGS licensing, microarray PGS
testing would quickly negate the efficacy of such an approach. For instance, the
agency might prohibit PGS solely for non-medical sex selection on the basis that
the benefit of selecting for a girl does not outweigh the risks that the child will
incur during the procedure. For a couple undergoing PGS to screen for a severe
disorder, denying the license for broad non-medical sex selection would
eliminate the opportunity to select girls from the remaining healthy embryos,
even though this selection would pose no risk to the offspring. Any use of PGS
that the agency could deny solely based on risk to the children from the PGS
procedure could become permissible if paired with screening for a more severe
genetic condition that would outweigh this risk.
325. Id. at 58.
326. Id. at 24.
327. Id.
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The government could attempt to license those uses that qualify as
"clinically indicated," such that the benefits of engaging in PGS outweigh the
risks, so that other tests, like non-medical sex selection, could be licensed for use
only in combination with a clinically indicated use. Advances in PGS could also
confound this approach, as the benefit of screening for numerous genetic
conditions at once may outweigh the risks to the offspring of conducting PGS,
even if no singular test on its own would warrant the use of PGS. In the absence
of demonstrated individual or social risk from sex selection, prohibiting it in all
cases would fail to give sufficient weight to parental autonomy.
In light of these challenges, the government should not seek to evaluate each
individual use or combination of uses, as this approach would be extremely
burdensome and unlikely to produce the desired effect. Instead, the government
should attempt to establish an infrastructure that enables it to monitor PGS use
for potential risks to offspring and society, provide guidance on appropriate uses,
and place restrictions on uses only when their harms clearly outweigh their
benefits.
c. Balancing Framework
Given the political climate and constitutional freedoms in the United States,
neither the indications framework nor the severe impairment requirement offers a
viable policy option. To resolve conflicts of interest between protecting
reproductive autonomy and protecting individuals and society from unjust harms
associated with ART use, the United States should adopt a decisional framework
based on the interests at stake and their relative importance. Following current
practice and Mill's principle the regulation of ART practice should originate
from a position of parental autonomy and sanctity of the medical profession.
Under this approach, individuals and their physicians would be able to decide
whether to use ART procedures, including PGS, to screen for any condition
without governmental approval. However, this right would not be absolute: their
autonomy must be balanced against the government's interest in protecting
individuals and society.
Such a balancing approach would suggest the need for immediate
governmental action, as well as monitoring to determine when future action is
required. Currently, the agency should restrict those medical practices in which
the clinical benefit is outweighed by the risk to the child. For instance, parents
and physicians often opt to transfer more than one embryo to the uterus to
improve the odds of pregnancy, but this practice also increases the health risk to
each embryo transferred.328 In order to diminish the number of multiple births,
328. See Bonduelle et al., supra note 15, at 418; Hansen et al., supra note 97, at 729; Klemetti et
al., supra note 14, at 1822; Soini et al., supra note 93, at 605-07.
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the agency could decide to restrict the number of embryos transferred.329 The
agency should also require clinics to maintain a strict code of medical ethics,
such that PGS will only be provided when clinically indicated. The agency
should provide practice guidelines to assist physicians in determining whether a
specific procedure is clinically indicated, but the ultimate decision in any
individual case should belong to both the physician and parents. Physicians are
trained to make decisions regarding the risk-benefit ratio of a specific procedure
and are better suited to make those decisions in individual circumstances.
However, the government should require the clinics to report their use patterns,
disclose success rates, and monitor clinic use patterns for repeat or egregious
inappropriate uses. The government should also perform on-site inspections to
ensure the accuracy of the reporting. In cases of abuse, the agency could suspend
or revoke the license of the clinic.
In the future, the government should also reserve the right to restrict PGS
use to select for certain alleles that would risk significant harm to society. For
instance, if the practice of sex selection, on its own or as part of multi-use PGS,
began to demonstrate significantly uneven selection patterns between males and
females, as has occurred in China and India,330 the agency should prohibit PGS
for non-medical sex selection. The agency might also have the ability to limit
PGS use to demonstrate its respect for unborn human life even in the absence of
individual or social risk. 331 The government's interest in protecting unborn life,
which grows as the embryo matures, 332 would be quite limited at the
preimplantation stage. But in some instances, the countervailing parental interest
in selecting a specific gene variant may be minimal as well. The parental interest
in selecting embryos based on non-medical characteristics of scant importance,
such as eye color, may not outweigh the government's interest in demonstrating
respect for the human embryo by not discarding it for a trivial purpose. In these
situations, the government may wish to restrict certain uses of PGS in the
absence of individual risk.
As genetic testing capabilities improve and the understanding of PGS risks
develops, the challenges of balancing the respective interests will increase in size
and magnitude. To mitigate the potential harms associated with unrestricted PGS
use, Congress should develop the infrastructure necessary to address the current
risks of PGS use as well as those visible on the horizon.
329. See Practice Comm., supra note 100, at S51-52.
330. See, e.g., Parliamentary Office of Sci. & Tech., Sex Selection, POSTNOTE 198, Aug. 2003,
at 4, available at http://www.parliament.uk/post/pn198.pdf.
331. Gonzales v. Carhart, 127 S. Ct. 1610 (2007).
332. Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833, 869 (1992).
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C. Assisted Reproductive Technology Authority
The preceding arguments suggest that Congress should create a national
independent regulatory body, the Assisted Reproductive Technology Agency
(ARTA), to perform five main functions: 1) establish a licensing system for ART
clinics; 2) establish procedural guidelines and regulations for ART practice; 3)
gather data on ART procedures, including PGS, long-term offspring and maternal
health outcomes, and public sentiment; 4) monitor that data for individual and
social risks; and 5) in the case that proven risks outweigh the benefits for certain
procedures, regulate the use of PGS for certain indications using the novel
balancing framework proposed above.
1. Procedural Regulations
ARTA's first responsibility will be to establish procedural requirements for
ART clinics. All ART clinics should be required to obtain a license from ARTA.
Licensing will signify that the clinic has met and continues to maintain certain
minimum standards of safety, quality of care, and expertise. ARTA should
require a license for clinicians who seek to perform highly technical procedures
such as egg retrieval and embryo biopsy. Clinics should offer patients genetic
counseling services by licensed genetic counselors. ARTA should also work with
ASRM and SART to establish best practices guidelines for ART procedures. In
addition to the laboratory regulations established by CLIA, ARTA should license
genetic testing laboratories that perform tests for PGS. 333 These laboratories
should meet standards of accuracy, quality control, and quality assurance set by
ARTA in order to obtain and maintain a license.
ARTA should then begin more long-term projects. First, the agency should
create a database of information on all ART procedures occurring in licensed
clinics. The CDC's requirements under FCSRCA should be turned over to ARTA
and expanded to include additional information, including the number of
embryos created, screened and transferred; the genetic and chromosomal analysis
performed; implantation and pregnancy rates; multiple gestations, including
information on reductions and live births; and infant health status. Parents should
be asked to consent to providing their child's annual health status report to obtain
health information from a representative sample of children born via PGS.3 34
333. If CMS eventually develops a genetic testing specialty and proficiency requirements that
specifically address the quality of genetic tests for PGS, then ARTA could relinquish this
responsibility to CMS.
334. Some parents may want to avoid having their children become permanent research
subjects; however, since PGS has never been vetted through a randomized control trial for health
outcomes, monitoring the children's health status is incredibly important. These health reports can
be provided without significant burden to the parents or child via annual physician check-up reports
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Women who undergo ART procedures should also be asked to provide updated
reports of their health status at regular intervals. Due to the uncertainties
associated with the current and future uses of PGS, more information is greatly
needed to adequately regulate the procedure. By encouraging those who engage
in PGS to provide information on their health outcomes, success rates, and
reasons for using the technology, ARTA can effectively determine where
government intervention is required. This would also enable ARTA to regulate
without resorting to a precautionary approach that would require the agency to
act before evidence of clear need. The license and monitoring approach of ARTA
could provide a policy solution that lies between the United States' current
laissez-faire approach and the precautionary tactics seen in many other nations
that have either banned or heavily regulated PGS.335
ARTA should monitor the database to identify adverse health outcomes, the
most common uses of PGS, possible discriminatory uses, and other issues of
individual or social concern, including socio-economic and demographic use
patterns. To maintain individual confidentiality, clinicians should remove all
identifying data. As more non-disease-related genetic screening becomes
available, ARTA should monitor the volume and popularity of such practices to
determine if more rigorous standards of regulation are necessary. 336 For non-
disease related indications, ARTA should examine closely whether the risks and
burdens of undergoing PGS to screen out the trait outweigh the potential benefit
of selection.
ARTA should provide information to enhance the understanding of issues
associated with reproductive genetics and PGS. It could work in collaboration
with genetic counselors and clinic providers to develop educational tools to
improve comprehension of the risks and benefits of PGS, as well as the
alternatives available to prospective parents. ARTA should conduct research on
the data collected in the database and make the data available to the public for
independent research. In addition to promoting scholarly publications and
research, ARTA should provide materials and programs to help laypersons
understand the issues surrounding assisted reproduction and genetics. Efforts to
educate and engage the public in conversation about ART and PGS will help
ensure that policies created in this area reflect the needs and concerns of society
as a whole, not just those with immediate financial or personal interests.
To determine the impact of certain indications, ARTA should work with a
diverse array of individuals, including geneticists, pediatricians, members from
the disability community, prospective parents, religious leaders, and others, to
until the child is eighteen, and then with the adult child's permission, on an every five-year basis
after that. See Soini et al., supra note 93, at 611.
335. 1 am indebted to Amitai Aviram for this helpful description of the ARTA proposal.
336. PRESIDENT'S COUNCIL, supra note 112, at 197-98.
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create PGS selection guidelines and decision analysis algorithms. This should be
an ongoing project with public opportunities for input and transparency. These
guidelines would be non-binding, but meant to assist clinicians and parents in
determining whether undergoing PGS for a particular purpose or discarding
embryos due to the presence of a specific allele is appropriate. ARTA's main role
in establishing PGS selection guidelines would be to determine the social impact
of various uses of PGS.
2. Substantive Regulations
In addition to creating and monitoring a database, establishing a licensing
system, and developing practice and PGS selection guidelines, ARTA should
establish a system for regulating the appropriate and inappropriate uses of PGS as
they arise, as well as mechanisms to identify and address many of the social risks
associated with PGS.
Initially, ARTA should permit parents and physicians to use PGS for any
purpose for which they believe the benefits of the selection outweigh the risks to
the offspring, mother, and society. The agency should create PGS selection
guidelines to assist physicians in accounting for the benefit of selecting a child
with a certain trait, the scientific accuracy of the genetic tests, the potential
individual risks to the mother and offspring, the overall demand for the
procedure, and the likely harm to others that might arise from its widespread use.
The first substantive standards ARTA should establish are those targeting
the accuracy and reliability of genetic tests that may be used in PGS. Genetic
tests for genes with low penetrance or low predictive value may be inappropriate
for PGS. Likewise, the agency should establish minimum levels of association
between the genetic loci tested for and the specific phenotype or physical
characteristic of interest, and then require all genetic associations to be
replicated with high reliability and without refutation before permitting the
testing to be used in PGS.
To address potential social harms, ARTA should take steps to reduce the
barriers to access for clinically indicated uses of ART for all members of society.
ARTA should use information from the database to identify disparities in access
as they arise and to determine factors contributing to the cause. The government
could also seek to engage and inform the public about the available treatment
choices and the risks and benefits that accompany them. If the barriers are
financial, the governmental efforts could improve access to insurance coverage
or provide subsidies for low-income families.337 In addition, any attempt to
encourage individuals to select for or against any specific conditions may be
337. However, any attempts to do so should be weighed against other health priorities.
Subsidies for ART may not become a priority for some time, if ever.
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viewed as discriminatory or eugenic. With respect to PGS, efforts to reduce
health disparities both in use of PGS itself or through selection for or against
genetic conditions should be made solely with the goal of helping individuals
obtain the necessary information and services to fulfill their health care goals.
The government should neither encourage nor discourage the use of PGS in any
particular group.
To address harms associated with discrimination, ARTA should examine
whether the screening results in balanced or one-sided selection patterns, and
whether those patterns reflect possible discrimination. For instance, concerns
about sex selection in the United States have been tempered by the fact that
prospective parents tend to select for boys and girls at similar rates. If parents
began systematically selecting boys for non-medical reasons, especially if based
upon discriminatory beliefs about the value of women, the government could
pass regulation prohibiting this practice. Determining whether collective choices
reflect discriminatory practices and at what point those choices create social
harm will be one of ARTA's main tasks. Only through expert analysis of PGS
use patterns and public sentiment could ARTA determine if such stigma and
discrimination rose to the level of generating a social risk.
By putting a regulatory system in place to ensure the safety and efficacy of
clinical practice and monitoring the use of PGS in the United States, we can gain
many of the benefits associated with PGS, while preparing to identify and
respond in a fast and efficient manner to any harms as they develop.
CONCLUSION
With little consideration for American preparedness, a technological
revolution in reproduction is coming. Recent advances in DNA microarrays and
bioinformatics will enable parents to select embryos based on a broad range of
genetic information. While this information will offer prospective parents
unprecedented decision-making capabilities regarding their future children,
unregulated use of the technology poses significant risk to women, children, and
society as a whole. To address these concerns, this Article advocates the creation
of a novel regulatory system that establishes the middle ground between the
current laissez faire approach and the precautionary approach taken in other
countries. Under this system, the ARTA will provide both procedural and
substantive regulation over the practice of assisted reproduction. Procedurally,
ARTA should license all ART clinics and genetics laboratories that provide
services for PGS, create a database of information on ART health outcomes and
practice patterns, and monitor the database for risks to individuals and society.
Substantively, the ARTA should establish a balancing framework that weighs
various interests based on the priority and strength of the interest to determine
whether certain ART practices should be regulated. Creating this infrastructure
now will promote the safety of those individuals currently engaged in ART
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practices, the informed choice of those seeking to use IVF and PGS in the future,
and the ability of the United States to adapt appropriately as new challenges
emerge.
Without question, passing any substantial legislation to establish a new
regulatory entity will prove extremely challenging, especially laws that regulate
reproductive practices. However, America's current lack of oversight and
regulation over ART, and especially PGS, invites significant social change
without pausing to consider what is at stake. While the proposal put forth in this
Article may change during the regulatory process, I hope that it will contribute to
the body of literature on the regulation of ART, stimulate further discussion of
the implications of PGS, and serve as a sound beginning to the establishment of a
regulatory framework for PGS.
One of the most challenging questions we face is how PGS use will impact
the everyday lives of Americans. If widely used, PGS has the potential to
dramatically change the way we reproduce, think about and relate to our children,
perceive other members of society, and value pre-nascent human life. Without
monitoring the use patterns of PGS and the public sentiment regarding current
and future capabilities of the procedure, we have no way to predict the potential
social impact of PGS. By pausing now to consider the future society we hope to
create for our children, we will have a better chance of making it a reality.
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